




HDPHARMA[®]

SINCE 1961

Fly high with time



**HAI DUONG PHARMACEUTICAL
MEDICAL MATERIALS JOINT
STOCK COMPANY
ANNUAL REPORT 2025**

TABLE OF CONTENTS

MESSAGE FROM THE CHAIRMAN OF THE BOARD OF DIRECTORS	2
COMPANY OVERVIEW	6
GENERAL INFORMATION	7
BUSINESS LINES	1Error! Bookmark not defined.
ORGANIZATIONAL STRUCTURE	16
DEVELOPMENT ORIENTATION	167
RISK FACTORS	19
BUSINESS PERFORMANCE	23
BOARD OF MANAGEMENT	24
HUMAN RESOURCE	32
FINANCIAL SITUATION	33
SHAREHOLDING STRUCTURE	36
REPORT AND ASSESSMENT BY THE BOARD OF DIRECTORS	37
ASSESSMENT OF BUSINESS PERFORMANCE	37
FINANCIAL POSITION	37
IMPROVEMENTS IN MANAGEMENT STRUCTURE AND POLICIES	38
FUTURE DEVELOPMENT PLAN	40
BOARD OF DIRECTORS' EVALUATION OF COMPANY OPERATIONS	43
BOARD OF DIRECTORS' EVALUATION OF ALL ASPECTS OF OPERATIONS	43
STRATEGIC ORIENTATION OF THE BOARD OF DIRECTORS	49
BOARD OF DIRECTORS	50
SUPERVISORY BOARD	53
REMUNERATION, COMPENSATION AND OTHER BENEFITS	55
SHARE TRANSACTIONS OF INTERNAL SHAREHOLDERS	55
SUSTAINABLE DEVELOPMENT REPORT	57
GENERAL INFORMATION ON SUSTAINABLE DEVELOPMENT REPORT	58
ENERGY CONSUMPTION	59
WATER CONSUMPTION	60
EMPLOYEE-RELATED POLICIES	61
COMMUNITY RESPONSIBILITY	66
AUDITED FINANCIAL STATEMENTSFrom 67 to 102



MESSAGE FROM THE CHAIRMAN OF THE BOARD OF DIRECTORS



Mr. Nguyen Trung Viet – Chairman of the Board of Directors

Dear Shareholders and Investors,

In 2025, both the global and Vietnamese economies continued to be significantly affected by the Russia-Ukraine war, economic tensions between Russia and the European Union and the United States, territorial conflicts in the Middle East, reciprocal tariffs imposed by the United States, and severe natural disasters and flooding..... in the latter half of the year. These factors disrupted global supply chains, leading to shortages and rising costs of raw materials for production. Many enterprises were forced to scale down operations, suspend production, or even declare bankruptcy. Inflationary pressures and rising prices, coupled with a contraction in domestic consumption, difficulties in international trade, and increasing warehousing and transportation costs, have collectively contributed to a prolonged global economic downturn.

The pharmaceutical industry has not been immune to these impacts. In addition to general challenges, our Company has faced intense market competition from multinational pharmaceutical corporations with decades of experience investing in Vietnam, as well as domestic enterprises rapidly expanding their production and business activities. Furthermore, regulatory policies within the pharmaceutical sector, including manufacturing standards and management requirements, have undergone significant changes.

The Company currently operates six GMP-WHO-compliant production lines and one EU-GMP-compliant production line, covering a diverse range of dosage forms, thereby generating employment opportunities and enhancing the Company's profitability.

To meet the requirements of Vietnam's pharmaceutical industry and support sustainable corporate growth, the Company has proactively undertaken both reinvestment and new investments in terms of scale and depth, with a focus on adopting the most advanced manufacturing technologies. The Company's current market capitalization is approximately VND 1,400 billion, representing a remarkable milestone achieved over more than a decade of continuous growth. The reinvestment process to complete the remaining production line projects requires a higher level of capital and asset value. In 2025, the Company is implementing Phase II of the HDPHARMA EU Factory Project, which involves the construction of two pharmaceutical production lines, including sterile powder injections and Betalactam tablets under the

Cephalosporin antibiotic group, in compliance with EU-GMP standards, with a total investment of VND 415 billion. The project is expected to be completed in 2026. Also in 2025, the Company's non-Betalactam tablet, granule, and effervescent production line was successfully re-certified in accordance with EU-GMP standards and has been put into operation, delivering EU-standard products. These products have been successfully awarded bids in the ETC channel and are widely distributed through the OTC system. This achievement marks a significant milestone in elevating the Company's manufacturing standards, reflecting the persistent efforts and dedication of the Board of Directors, the Management Board, and the Company's workforce over many years.

Building on these achievements, the Company will continue to optimize its operational efficiency, overcome economic challenges, and reaffirm its commitment to executing its long-term development strategy:

HDPHARMA strives to become a symbol and one of the leading brands in Vietnam's healthcare sector, consistently delivering the highest quality products and meeting customers' expectations for a healthy and sustainable life.

Strategic Pillars of the Company

The Company's strategy is built upon three key directions, forming three core pillars:

1. Developing a Modern Manufacturing System

- Focusing on key production lines rather than individual key products;
- Strengthening research and development (R&D) as a primary factor influencing product quality;
- Recognizing quality as a critical element in pharmaceutical manufacturing

2. Developing a professional and modern business system with a nationwide distribution network.

3. Establishing a marketing-oriented approach across all Company activities.

Key Objectives

- Modernize and enhance the manufacturing system toward advanced production standards
- Position HDPHARMA brands among leading brands in the market
- Maximize market share of the Company's manufactured product portfolio
- Expand distribution coverage and increase market penetration of self-manufactured products
- Develop HDPHARMA into a company managed under modern standards, with standardized processes and procedures
- Develop human resources aligned with the values of aspiration, modernity, dedication, and professionalism
- Strengthen joint ventures and partnerships with major pharmaceutical corporations to enhance production and business activities, including cooperation in developing shared production lines

Key Action Plans

- At Plant No. 1 (No. 102 Chi Lang):
 - + Replace the existing injection production line with a modern system and increase production capacity
 - + Invest in BFS production lines for ophthalmic, nasal, and inhalation products

+ Consider investment in a liquid fermentation production line

- At HDPHARMA EU Factory:

+ Validate and commission two Cephalosporin production lines in Building 4C in compliance with EU-GMP standards

+ Initiate the design and construction of Building 4B, including three EU-GMP-compliant production lines

+ Construct Building 4D and the office building

- Optimize and further develop production across existing manufacturing lines;

- Strengthen cooperation with global partners and major pharmaceutical corporations to achieve breakthrough revenue growth;

- Promote export activities;

- Upgrade, modernize, and develop the Company's business system

Dear Shareholders and Investors, Despite the challenges ahead, we have no alternative but to move forward and overcome them. With dedication, intelligence, and unity, all members of HDPHARMA are committed to achieving the Company's strategic goals and realizing our vision of becoming a leading pharmaceutical enterprise.

I sincerely hope that our shareholders will continue to support and accompany the Company as we strive toward new heights in the future. On behalf of the Board of Directors, I also commit to strictly monitoring the use of every financial resource to ensure effective and efficient investment.

Finally, I would like to express my deepest gratitude and best wishes to our valued shareholders, partners, and customers. I would also like to extend my sincere thanks to all employees for their dedication and contributions over the years. Hai Duong Pharmaceutical Medical Materials Joint Stock Company will continue to grow stronger and further in order to meet the trust and support you have placed in us.

Chairman of the Board of Directors



**CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT**

VISION

To develop Hai Duong Pharmaceutical Medical Materials Joint Stock Company into one of the leading enterprises in Vietnam's pharmaceutical industry, while building a modern, integrated manufacturing system that complies with GMP-WHO and EU-GMP standards and offers a diverse portfolio of pharmaceutical products. HDPHARMA is committed to delivering the highest overall quality and meeting customers' expectations for a healthy and fulfilling life.

MISSION

For Shareholders and Investors: To maximize shareholder value, enhance transparency, and ensure timely disclosure of the Company's operational information to shareholders and investors, while proactively creating opportunities for engagement and dialogue with investors.

For Customers: To provide high-quality products with long-term stability; to continuously listen and strengthen technical and technological capabilities in order to best meet customer needs.

For Business Partners: To maintain, nurture, and develop long-term relationships based on the principle of mutual benefit, aiming to deliver the highest quality products to society.

For Society: HDPHARMA is committed to fulfilling its social responsibilities by actively engaging in meaningful community initiatives, contributing to the enhancement of skills and professional capacity of the workforce, and supporting the sustainable development of society.

For Employees: To value employees' contributions by fostering a friendly working environment, encouraging independent thinking and creativity, and supporting their role in the Company's development.

COMPANY OVERVIEW

GENERAL INFORMATION

KEY ACHIEVEMENTS

HISTORICAL MILESTONES

BUSINESS OPERATING AREAS

COMPANY BRANCHES AND KEY CUSTOMERS

BUSINESS LINES

ORGANIZATIONAL STRUCTURE

DEVELOPMENT ORIENTATION

RISK FACTORS

THÔNG TIN CHUNG

Trading Name: Hai Duong Pharmaceutical Medical Materials Joint Stock Company

English name HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JOINT STOCK COMPANY



Head Office Address: No. 102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

Business Registration Certificate: No. 0800011018 issued by the Hai Duong Department of Planning and Investment, first issued on April 4, 2003, with the 23rd amendment dated July 16, 2025.

Registered Charter Capital: 359.959.290.000 VND

Paid-up Charter Capital: 359.959.290.000 VND

Telephone 0220.3853.848

Fax 0220.3853.848

Website <http://hdpharma.vn/>

Stock code DHD


DEVELOPMENT HISTORY



Hai Duong Pharmaceutical Medical Materials Joint Stock Company (HDPHARMA) is a joint-stock company equitized from a state-owned enterprise. Since its establishment, the Company's formation and development have been closely associated with the growth of Vietnam's pharmaceutical industry, as well as the various stages of the country's economic development. The Company's development process can be summarized through the following key milestones:

<p>➤ 1961</p> <p>The Hai Duong Provincial Administrative Committee established the State-owned Pharmaceutical Enterprise.</p>	<p>➤ 1966</p> <p>The State-owned Pharmaceutical Enterprise was reorganized into two independent administrative entities: Hai Hung Provincial Pharmaceutical Enterprise and Hai Hung Provincial Pharmaceutical Factory.</p>	<p>➤ 1982</p> <p>The Hai Hung State-owned Pharmaceutical Enterprise and Hai Hung Pharmaceutical Factory were merged into the Hai Hung Pharmaceutical Union Enterprise.</p>	<p>➤ 1988</p> <p>The Hai Hung Pharmaceutical Union Enterprise was renamed Hai Duong Pharmaceutical Medical Materials Company.</p>
<p>➤ 2003</p> <p>Hai Duong Pharmaceutical Medical Materials Company was converted into Hai Duong Pharmaceutical Medical Materials Joint Stock Company with a charter capital of VND 10.26 billion.</p>	<p>➤ 2007</p> <p>Hai Duong Pharmaceutical Medical Materials Joint Stock Company adopted "HDPHARMA" as its trading name.</p>	<p>➤ 2010</p> <p>The Company increased its charter capital from VND 10.26 billion to VND 30 billion through share issuance to existing shareholders, employees, and strategic investors.</p>	<p>➤ 2018</p> <p>The Hai Duong Department of Planning and Investment issued the 14th amended Business Registration Certificate, Enterprise Code: 0800011018, with a charter capital of VND 60,000,000,000.</p>

<p>➤ 2019</p> <p>2019: The Company converted VND 20 billion of convertible bonds into shares for shareholders. October 28, 2019: The Hai Duong Department of Planning and Investment issued the 15th amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 80,000,000,000.</p>	<p>➤ 2020</p> <p>2020: The Company paid dividends to shareholders for 2019 in accordance with the Resolution of the 2020 General Meeting of Shareholders, totaling VND 19,999,450,000. May 28, 2020: The Hai Duong Department of Planning and Investment issued the 17th amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 99,999,450,000.</p>	<p>➤ 2021</p> <p>2021: The Company paid dividends to shareholders for 2020 in accordance with the Resolution of the 2021 General Meeting of Shareholders, totaling VND 19,999,430,000. May 26, 2021: The Hai Duong Department of Planning and Investment issued the 18th amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 119,998,880,000.</p>	<p>➤ 2022</p> <p>2022: The Company paid dividends to shareholders for 2021 in accordance with the Resolution of the 2022 General Meeting of Shareholders, totaling VND 29,998,970,000. July 26, 2022: The Hai Duong Department of Planning and Investment issued the 19th amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 149,997,850,000.</p>
<p>➤ 2023</p> <p>2023: The Company issued shares to increase charter capital from equity for existing shareholders in accordance with the Resolution of the 2023 General Meeting of Shareholders, totaling VND 53,998,450,000. June 7, 2023: The Hai Duong Department of Planning and Investment issued the 20th amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 203,996,300,000.</p>	<p>➤ 2024</p> <p>2024: The Company issued shares to increase charter capital from equity for existing shareholders in accordance with the Resolution of the 2024 General Meeting of Shareholders, totaling VND 75,476,870,000. June 7, 2024: The Hai Duong Department of Planning and Investment issued the 21st amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 279,473,170,000.</p>	<p>➤ 2025</p> <p>2025: The Company issued shares to increase charter capital from equity for existing shareholders in accordance with the Resolution of the 2025 General Meeting of Shareholders, totaling VND 80,486,120,000. May 29, 2025: The Hai Duong Department of Planning and Investment issued the 22nd amended Business Registration Certificate (Enterprise Code: 0800011018), with a charter capital of VND 359,959,290,000.</p>	<p>➤</p> <p>From July 1, 2025: In accordance with the Government's policy on the merger of Hai Duong Province and Hai Phong City under the name Hai Phong City, the Company updated its Business Registration Certificate with a new registered address: No. 102 Chi Lang Street, Thanh Dong Ward, Hai Phong City.</p>



CHI NHÁNH CÔNG TY VÀ MỘT SỐ KHÁCH HÀNG TIÊU BIỂU

- Hai Duong**
Head Office of Hai Duong Pharmaceutical Medical Materials Joint Stock Company
Address: No. 102 Chi Lang Street, Nguyen Trai Ward, Hai Duong City, Hai Duong Province, Vietnam
- Hanoi**
Company Office and Hanoi Branch of Hai Duong Pharmaceutical Medical Materials Joint Stock Company
Address: Land Lot No. 01, D6C Block, Land Auction Area, Xuan La Ward, Tay Ho District, Hanoi, Vietnam
- Tuyen Quang**
Tuyen Quang Pharmaceutical Company
- Hai Phong**
Hau Vu Pharmaceutical Co., Ltd.
Minh Nhat Pharmaceutical Co., Ltd.
- Dien Bien**
Dien Bien Pharmaceutical Joint Stock Company
- Hoa Binh**
Ha Viet Pharmaceutical Co., Ltd.
- Son La**
Duong Hong Thuy Pharmaceutical Joint Stock Company
- Bac Ninh**
Bac Ninh Pharmaceutical Joint Stock Company
- Bac Giang**


- Bac Giang Pharmaceutical Joint Stock Company
Ngoc Dong Pharmaceutical Co., Ltd.
10. **Thai Nguyen**
Hoang Lan Pharmaceutical Co., Ltd.
Huu Yen Pharmaceutical Co., Ltd.
11. **Lang Son**
Thanh Cong Pharmacy
12. **Quang Ninh**
Hai Binh Co., Ltd.
13. **Nam Dinh**
Nam Ha Pharmaceutical Co., Ltd.
Toan Anh Pharmaceutical Company
14. **Vinh Phuc**
Vinh Phuc Pharmaceutical Joint Stock Company
Hai Nga Pharmaceutical Co., Ltd.
15. **Ho Chi Minh City**
Branch of Hai Duong Pharmaceutical Medical Materials Joint Stock Company in Ho Chi Minh City
Address: 99 Street No. 101, Thanh My Loi Ward, District 2, Ho Chi Minh City, Vietnam
16. **Da Nang**
Central Branch of Hai Duong Pharmaceutical Medical Materials Joint Stock Company
Address: Lot 9 – C4, Hoa Phat 4 Residential Area, Hoa An Ward, Cam Le District, Da Nang City, Vietnam
17. **Dak Lak**
Dak Lak Pharmaceutical Medical Materials Joint Stock Company
18. **Lam Dong**
Lam Dong Pharmaceutical Joint Stock Company
19. **Ninh Thuan**
Ninh Thuan Pharmaceutical Medical Materials Joint Stock Company
20. **Can Tho**
Can Tho Branch of Hai Duong Pharmaceutical Medical Materials Joint Stock Company
Address: Lot 09–53–54, Street No. 7, Stella Residential Area, Binh Thuy Ward, Binh Thuy District, Can Tho City, Vietnam

BUSINESS LINES

- Manufacturing of pharmaceuticals, chemical pharmaceuticals, and medicinal materials
- Manufacturing of medical, dental, orthopedic, and rehabilitation equipment and instruments
- Manufacturing of functional foods
- Manufacturing of cosmetics
- Wholesale of pharmaceuticals and medical devices
- Wholesale of functional foods
- Wholesale of perfumes, cosmetics, and hygiene products
- Wholesale of other chemicals (excluding those used in agriculture)
- Wholesale of machinery and medical equipment
- Wholesale of essential oils, medicinal materials, and optical products
- Retail of pharmaceuticals, medical devices, cosmetics, and hygiene products in specialized stores
- Retail of functional foods in specialized stores
- Retail of watches and optical products in specialized stores
- Cultivation of medicinal plants
- Farming of geckos and snakes (as permitted by law)
- Printing services
- Provision of scientific and technical consulting and technology transfer services in the fields of healthcare, pharmaceuticals, cosmetics, and food; quality testing services for pharmaceuticals and functional foods

- Freight transport services by road
- Agency services for pharmaceuticals, cosmetics, functional products, medical devices, medical equipment, optical products, medicinal materials, essential oils, and chemicals
- Leasing of offices, warehouses, yards, retail premises, and residential properties
- Hotel business and beauty care services
- Distillation, rectification, and blending of spirits
- Production of wine, beer, malt, and non-alcoholic beverages, including mineral water
- Construction of buildings of all types

PRODUCT PORTFOLIO:




Handwritten text in red ink, possibly a page number or date, located on the left margin.





CƠ CẤU BỘ MÁY QUẢN LÝ



GENERAL MEETING OF SHAREHOLDERS

The General Meeting of Shareholders is the highest decision-making body of the Company, responsible for making decisions on matters as stipulated by applicable laws and the Company's Charter.

BOARD OF DIRECTORS

The Board of Directors is the governing body of the Company, consisting of three (03) members elected or dismissed by the General Meeting of Shareholders. The Board of Directors has the authority to act on behalf of the Company in deciding and exercising the Company's rights and obligations, except for matters falling under the authority of the General Meeting of Shareholders. The Company's business operations and activities are subject to the supervision and direction of the Board of Directors.

SUPERVISORY BOARD

The Supervisory Board is responsible for overseeing the activities of the Board of Directors and the General Director in managing and operating the Company. It consists of three (03) members.

GENERAL DIRECTOR

The General Director is appointed by the Board of Directors and is the highest executive responsible for the day-to-day operations of the Company. The General Director has full authority to make decisions and exercise the Company's rights and obligations in accordance with regulations, except for matters under the authority of the General Meeting of Shareholders, the Board of Directors, and the Supervisory Board.

DEVELOPMENT ORIENTATION

Objectives

To develop a modern, integrated manufacturing system in compliance with GMP-WHO and EU-GMP standards, offering a diverse portfolio of pharmaceutical products. The system of production lines includes:

Soft capsule production line (non-Betalactam antibiotics)

Injectable solution production line (non-Betalactam antibiotics)

Ophthalmic and nasal solution production lines (non-Betalactam antibiotics), along with production lines for tablets, powders, granules, syrups, oral liquids, topical medicines, medicated alcohols, and herbal extracts derived from medicinal materials

Cream, ointment, and gel production lines (non-Betalactam antibiotics)

Tablet, granule, and effervescent production line (non-Betalactam antibiotics) compliant with EU-GMP standards

Cosmetic and medical consumables production lines

Pharmaceutical production lines for sterile powder injections and Betalactam tablets (Cephalosporin group) compliant with EU-GMP standards

BFS production lines for ophthalmic, nasal, and inhalation products

Planned investment in liquid fermentation production lines

To continuously improve and strengthen the management system and enhance product quality to meet EU standards.

Hai Duong Pharmaceutical Medical Materials Joint Stock Company aims to become an attractive, safe, efficient, and reliable partner for both domestic and international investors.

Development Strategy

Business Philosophy and Strategy

Taking service as the core business purpose and business efficiency as the driving force for development

Product and Service Quality Policy

Protecting and enhancing product quality as the core mission of the Company

Market and Sales Policy

Implementing comprehensive market coverage strategies and expanding distribution networks to remote and underserved areas, both domestically and internationally, to promptly meet customer needs

Branding and Promotion

Implementing promotional plans through national television channels (VTV1, VTV3), local broadcasting channels, newspapers, magazines, and corporate as well as external websites

Technology Innovation and Technical Improvement

Investing in modern machinery and equipment for existing production lines

Modernizing traditional medicine production lines in compliance with GMP-WHO standards

Upgrading liquid and semi-solid production lines to meet GMP-WHO standards

Expanding injectable production lines

Investing in BFS production lines for ophthalmic, nasal, and inhalation products

- Planning investment in liquid fermentation production lines
- Investing in EU-GMP-compliant pharmaceutical production lines, including sterile injections and Betalactam (Cephalosporin) products
- Investing in advanced manufacturing and quality control equipment

Human Resource Development Policy

- Expanding internal training programs and sponsoring advanced training for employees
- Inviting experts to provide technical training and technology transfer for employees directly involved in operations

Corporate Culture Development

- Promoting compliance with laws and internal regulations among employees
- Upholding corporate values, especially respect for product quality
- Building a professional working style with a positive, civilized, and courteous attitude
- Ensuring employee benefits, providing timely incentives and rewards to motivate employees, and creating favorable conditions for internal organizations to operate effectively


RISK FACTORS

ECONOMIC RISKS

Macroeconomic factors such as GDP growth, inflation, and foreign exchange rates have a direct impact on product consumption. Therefore, maintaining a stable economic growth rate in Vietnam is a key factor influencing overall market demand, promoting industrial output, and enabling enterprises to expand their market share. The effective implementation of macroeconomic policies by the Government is one of the critical factors in mitigating risks for domestic enterprises, including HDPHARMA.

Economic Growth

According to the General Statistics Office, the gross domestic product (GDP) growth rate for the year reached 8.02% compared to 2024, exceeding the target set by the National Assembly. The size of the economy reached approximately USD 514 billion, ranking 33rd globally, while GDP per capita reached USD 5,026.



This represents the second-highest growth rate during the 2021–2025 period.

In 2025, the National Assembly set a GDP growth target of 6.5%–7%, with GDP per capita expected to reach approximately USD 4,900. This target was considered highly challenging amid the global and domestic economic difficulties. To achieve this target, the National Assembly and the Government implemented a range of coordinated and effective policies and solutions aimed at minimizing the impacts of prolonged geopolitical conflicts, including the Russia–Ukraine war, territorial conflicts in the Middle East and the Red Sea, economic tensions between Russia and the European Union and the United States, as well as the severe consequences of multiple typhoons (Nos. 5, 9, 10, and 11) occurring consecutively in 2025. Despite these challenges, domestic production and business activities gradually recovered in 2025. GDP growth exceeded the target set by the National Assembly, creating a favorable environment for the development of Vietnam’s pharmaceutical industry.


Inflation

Inflation in Vietnam in recent years has shown complex fluctuations with significant volatility, creating price instability and indirectly affecting the revenue and profitability of enterprises. According to the General Statistics Office, Vietnam remains among countries with relatively low inflation compared to the global average. The average Consumer Price Index (CPI) in 2025 was recorded at 3.31%, a positive outcome within the National Assembly’s target of maintaining inflation below 4.5%, despite significant pressures from natural disasters and global energy price fluctuations.

To stabilize the macroeconomic environment and successfully control inflation, the Government directed ministries, sectors, and local authorities to implement a series of decisive measures in 2025, including ensuring smooth supply, circulation, and distribution of goods, particularly essential commodities serving daily needs.

Efforts were also strengthened in price management and regulation, especially during periods of natural disasters and floods, including timely allocation of national reserve goods to support affected populations. Prices of state-regulated goods and public services were adjusted cautiously in line with market-oriented mechanisms. Support policies related to taxes, fees, and charges were also continuously implemented to assist both individuals and enterprises. In addition, monetary policy was managed proactively, flexibly, and effectively, contributing to inflation control. Furthermore, the easing of global inflation helped reduce imported inflation pressures on Vietnam

Chỉ số lạm phát (CPI) bình quân Việt Nam giai đoạn 2021 - 2025



Interest Rate Risk

The Company is exposed to interest rate risk arising from its interest-bearing borrowings. This risk is managed by maintaining an appropriate balance between fixed-rate and floating-rate loans. The Company also proactively manages its capital structure and cash flows to optimize funding sources, thereby minimizing working capital requirements and borrowing costs.

Competitive Risk

Over recent years, the pharmaceutical industry has been regarded as a highly attractive sector, attracting significant investment inflows. As a result, numerous new manufacturing facilities have been and continue to be established, with increasingly large-scale and well-structured investments. This trend is expected to intensify competition in the coming years as these facilities become operational.

In addition, a notable trend in recent years and in the years ahead is the increasing presence of multinational pharmaceutical corporations entering the Vietnamese market. These corporations possess extensive experience in pharmaceutical manufacturing and distribution, advanced technologies, and substantial financial resources.

At the same time, domestic and international wholesale and retail distribution chains have been rapidly expanding, capturing and reshaping the pharmaceutical distribution market in Vietnam. Notable examples

include Long Chau, Pharmacy, and An Khang pharmacy chains. According to projections, the total number of outlets of these three retail chains is expected to reach approximately 4,500–5,000 by 2026, accounting for around 19%–22% of the market share.

This competitive landscape requires the Company to further enhance product quality, continuously upgrade technologies, diversify its product portfolio, and regularly introduce new-generation products at competitive prices that meet actual market demand. At the same time, the Company must develop a reputable and extensive distribution network, strengthening trust among healthcare professionals and consumers in order to sustain and enhance its competitive position in the market.

Other Risks

Other risks such as war, natural disasters, fire, and epidemics are considered force majeure events. Although these risks occur infrequently, they may cause significant damage to assets, human resources, and the overall operations of the Company if they arise. These risks cannot be entirely eliminated but can be mitigated. Therefore, the Company continuously monitors and updates relevant information in order to promptly implement preventive and responsive measures. At the same time, the Company strictly complies with applicable regulations and regularly conducts training on fire prevention and fighting, as well as occupational health and safety, to ensure effective risk management and preparedness.

Legal Risk

The Company's production and business activities are governed by various laws, including the Law on Enterprises, the Law

on Securities, and the Law on Pharmacy. However, the legal framework, including subordinate regulations, industry-specific provisions, and tax guidelines, is subject to frequent changes, lacks full consistency, and is still in the process of being refined. These factors may have an impact on the Company's business performance and strategic direction. Such changes may also give rise to potential risks of litigation, disputes, or compensation liabilities if the Company fails to fully understand or promptly update new regulatory requirements. To mitigate these risks, the Company places strong emphasis on continuously monitoring and updating legal developments, as well as engaging professional advisory services to ensure compliance in its production and operational activities. In addition, the Company has been and continues to invest in the training and development of in-house legal personnel to enhance its ability to promptly capture and apply relevant legal regulations.

Quality Management Risk

Currently, the Drug Administration of Vietnam has incorporated PIC/S standards into regulatory requirements. Pharmaceutical manufacturing is required to comply with GMP-WHO standards and strictly adhere to these requirements. The regulatory stance is clear: companies must meet all required manufacturing standards to continue operations; otherwise, they will not be permitted to manufacture. As a result, only enterprises with well-structured investments and standardized production systems will be able to sustain operations. The trend toward strict compliance and the

elimination of non-compliant enterprises is inevitable in the development of the pharmaceutical industry.

Following the implementation of Circular No. 15/2019, domestic pharmaceutical manufacturers have entered a race to establish EU-GMP-compliant production lines. Competition among EU-GMP-certified manufacturing facilities is expected to intensify in the medium term, involving not only capital investment but also product quality requirements.

Since 2020, Vietnamese pharmaceutical authorities have required the separation of health supplement production from pharmaceutical production. This means that companies wishing to produce both must effectively duplicate their production lines. This requirement, combined with declining consumer confidence and increasing competition in the health supplement market, has negatively impacted companies, including those engaged in contract manufacturing of such products.

Risks Specific to the Pharmaceutical Industry

Counterfeit and imitation products remain one of the most significant challenges facing pharmaceutical manufacturing and trading enterprises. Although the introduction of intellectual property laws has contributed to protecting enterprises and improving the competitive environment, this risk has not been completely eliminated. Pharmaceutical products are highly sensitive goods that directly affect human health and safety. In addition, the pharmaceutical industry requires substantial investment, long development timelines, and significant resources for research and development, while the success rate of new product trials remains relatively low. Furthermore, certain products such as specialty drugs and medicines for epidemic control must be maintained in inventory, posing risks of unsold stock. Given that pharmaceutical products have defined shelf lives, unsold inventory upon expiration may result in financial losses. To address these industry-specific risks, the Company must implement appropriate measures, including effective sales planning and inventory management, to ensure optimal product circulation and minimize potential losses.

Material Price Volatility Risk

Due to the nature of its manufacturing operations, the Company is directly affected by fluctuations in input material prices, as well as supply sources and origins of raw materials. In the pharmaceutical industry, product pricing is subject to strict government regulation, which limits the Company's ability to adjust output prices.

As a result, the Company is exposed to inherent risks arising from unpredictable fluctuations in input costs. In addition, while the global economy, including Vietnam, has yet to fully recover from the COVID-19 pandemic, ongoing geopolitical conflicts—such as the Russia-Ukraine war and tensions in the Middle East and the Red Sea—continue to disrupt global supply chains. This has led to shortages of pharmaceutical raw materials, increased input costs, and higher transportation expenses, forcing many enterprises to suspend operations or cease production. To mitigate these risks, the Company actively negotiates pricing with suppliers and proactively sources raw materials. The Company is also implementing projects to develop standardized medicinal material cultivation areas in compliance with GACP standards in Ninh Giang and Tu

Ky (Hai Phong City), aiming to ensure long-term stability of input material costs and supply for its production and business activities.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

OPERATING PERFORMANCE

Business Operations Performance

Board of Management

Human Resources

Financial Position

Investment Activities and Project Implementation

Shareholding Structure

BUSINESS OPERATIONS PERFORMANCE

Indicator	Unit	2025	2024	Change (%) 2025/2024
Net Revenue	VND	683.713.520.353	665.001.708.794	2,81%
Cost of Goods Sold	VND	438.734.362.525	454.770.265.987	-3,53%
Gross Profit	VND	244.979.157.828	210.231.442.807	16,53%
Financial Income	VND	1.217.152.638	633.188.787	92,23%
Financial Expenses	VND	5.681.886.282	6.255.488.148	-9,17%
Selling Expenses	VND	79.028.832.449	74.149.536.551	6,58%
General & Administrative Expenses	VND	93.156.777.114	81.814.791.647	13,86%
Operating Profit	VND	68.328.814.621	48.644.815.248	40,46%
Other Income	VND	1.436.746.884	2.143.693.425	-32,98%
Profit Before Tax	VND	69.765.561.505	50.788.508.673	37,36%
Profit After Tax	VND	55.703.190.202	40.608.780.696	37,17%

Revenue Overview

In 2025, net revenue increased by 2.81% compared to 2024. Although this growth did not fully meet the planned target, it reflects a positive recovery of the overall economy. It also demonstrates the effectiveness of the Company's strategic direction, particularly in production investment and the expansion of its distribution network.

Profit Analysis

- Net revenue in 2025 increased by 2.81% compared to 2024.
- The proportion of revenue from self-manufactured products reached 83.6% of total revenue, up 5.42% compared to 2024, contributing to an increase in the average gross profit margin by 4.06%.


- With both revenue and gross margin improving, gross profit increased by VND 34,747,715,021, equivalent to a growth rate of 16.53%. This served as the main driver for the increase in both profit before tax and profit after tax.
- Effective capital management and the optimization of financing sources resulted in financial cost savings of VND 40,072,654.
- Selling and administrative expenses were well controlled, increasing by VND 16,222,431,282 (equivalent to 10.4%), which is lower than the growth rate of gross profit.

As a result, profit after tax in 2025 increased by 37.17% compared to 2024.

Production Performance in 2025

(Unit: thousand VND)

Workshop	2025	2024	Change (%)
Injectable & Eye Drops Workshop	91,852,670	87,089,776	5.5%
Herbal Extract Workshop	36,628,234	38,070,609	-3.8%
Tablet Workshop	75,331,351	73,024,008	3.2%
Soft Capsule Workshop	92,627,999	84,182,129	10.0%
Cream & Ointment Workshop	22,208,042	18,960,449	17.1%
Tablet Workshop 2 – EU GMP	18,545,470	22,693,648	-18.3%
Oral Liquid Ampoule Workshop	7,865,225	9,840,948	-20.1%
Tablet Workshop 1 – EU GMP	37,393,974	16,260,482	130.0%
Total Output Value	382,452,965	350,122,049	9.2%



Production Planning: Production planning in 2025 faced significant challenges. The Company had to adapt its management approach and operational methods to align with an increasingly unstable global supply chain environment. This instability was driven by geopolitical conflicts, economic tensions across regions, and the constant risk of supply chain disruptions. In addition, raw materials became scarce, prices continued to rise, and logistics faced frequent bottlenecks, making the circulation of goods more difficult. At the same time, customer demand remained unpredictable and consumption trends fluctuated, resulting in reactive and imbalanced production planning. These factors negatively impacted both production efficiency and sales performance.

◆ **Production Output Value:** In 2025, the total production output value reached VND 382,452,965,000, representing: A decrease of 19.65% compared to the annual plan; An increase of 9.2% compared to 2024, equivalent to VND 32,330,914,000.

Assessment: In 2025, the Company did not achieve its target for production output value. The main reasons are as follows:

- ✓ The EU-GMP production lines have not operated consistently and have not yet generated high-value EU-GMP-compliant products as initially expected.
- ✓ The global economy has been recovering slowly following the COVID-19 pandemic. Prolonged geopolitical conflicts, including the Russia–Ukraine war and tensions in the Middle East, have led to disruptions in global consumption and logistics. Additionally, trade policies such as reciprocal tariffs imposed by major economies have negatively affected global production systems, supply chains, and consumption demand. Rising prices and global inflation have further weakened consumer purchasing power, resulting in decreased sales and consequently reduced production output.
- ✓ Although the Company has implemented a nationwide distribution system under its new business strategy, intense competition in the pharmaceutical sector and ongoing economic challenges have limited sales growth. While both self-manufactured products and contract manufacturing segments recorded growth compared to the previous year, the results still fell short of the targets set by the 2025 General Meeting of Shareholders.
- ✓ Despite these challenges, including severe natural disasters and prolonged flooding toward the end of 2025, production output still achieved a 9.2% year-on-year growth, reflecting the strong efforts and resilience of the Company’s management and workforce.

LIST OF KEY MANAGEMENT PERSONNEL

Board of Directors



Mr. Nguyen Trung Viet
Chairman of the Board of
Directors

Date of Birth: April 26, 1969
Educational Background: Bachelor of Social Sciences
Professional Experience:
◆ 1997 – March 2014: Chairman of the Board of Directors, Vinasun Group – Ukraine (Kiev)
◆ April 2014 – Present: Chairman of the Board of Directors, Hai Duong Pharmaceutical Medical Materials Joint Stock Company (HDPHARMA)
Current Positions: At the listed organization: Chairman of the Board of Directors, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
At other organizations: None
Shareholding: 14,702,263 shares, representing 40.84% of the Charter Capital



Mrs. Nguyen Thi Tu Anh
Member of the Board of
Directors cum Chief
Executive Officer

Date of Birth: September 1, 1965
Educational Background: Bachelor of Pharmacy
Professional Experience:
◆ February 1989 – October 1991: Drug Agent, Central Pharmacy – Hai Hung Pharmaceutical Union Enterprise
◆ November 1991 – July 1995: Head of Injectable Compounding Unit, Hai Hung Pharmaceutical Union Enterprise
◆ August 1995 – March 2003: Sales Representative, Hai Duong Pharmaceutical Medical Materials Company
◆ April 2003 – October 2011: Member of the Board of Directors cum Director, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
◆ November 2011 – March 2016: Member of the Board of Directors cum Deputy General Director, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
◆ April 2016 – Present: Member of the Board of Directors cum Chief Executive Officer, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
At other organizations: None
Shareholding: 1,363,191 shares, representing 3.99% of the Charter Capital.



Mr. Tran Phuc Duong
Member of the Board of Directors

Date of Birth: October 10, 1968

Educational Background: Bachelor of Economics

Professional Experience:

◆ 1989 – July 2015: Self-employed (Business Activities)

◆ August 2015 – Present: Working at Hai Duong Pharmaceutical Medical Materials Joint Stock Company (HDPHARMA)

Current Positions at the listed organization: Member of the Board of Directors, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

At other organizations: None

Shareholding: 1,461,926 shares, representing 4.06% of the Charter Capital

BAN KIỂM SOÁT



Mrs. Pham Thi Thuy
Head of the Supervisory Board

Date of Birth: May 2, 1971

Educational Background: Bachelor of Economics

Professional Experience:

◆ October 1992 – March 2015: Accounting Department Staff, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

◆ April 2015 – November 2015: Financial Inspector, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

◆ December 2015 – October 2016: Financial Inspector cum Assistant to the Chairman of the Board of Directors, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

◆ November 2016 – Present: Financial Inspector cum Assistant to the Chairman and Head of the Supervisory Board, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

Current Positions at the listed organization: Financial Inspector and Head of the Supervisory Board, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

At other organizations: None

Shareholding: 324,260 shares, representing 0.90% of the Charter Capital



Mr. Tran Kim Cuong
Member of the
Supervisory Board

Date of Birth: January 10, 1975

Educational Background: Bachelor of Pharmacy

Professional Experience:

♦ July 1996 – August 2004: Sales Representative, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ October 2004 – March 2009: Head of Chi Linh Pharmacy, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ April 2009 – Present: Branch Director cum Member of the Supervisory Board, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

Current Positions at the listed organization: Branch Director cum Member of the Supervisory Board, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

At other organizations: None

Shareholding: 185,664 shares, representing 0.52% of the Charter Capital



Bà Nguyễn Thị Hương
Lan
Thành viên Ban Kiểm
Soát

Date of Birth: August 6, 1987

Educational Background: Bachelor of Pharmacy

Professional Experience:

♦ December 2010 – December 2013: Business Operations Staff, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ January 2014 – February 2015: Deputy Head of Sales Department, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ March 2015 – June 2018: Deputy Head of Production Planning Department cum Member of the Supervisory Board, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ July 2018 – November 2020: Head of Production Planning Department, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ December 2020 – February 2022: Deputy Manager of Supply Department, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

♦ March 2022 – Present: Team Leader of Production Planning Unit, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

Current Positions at the listed organization: Member of the Supervisory Board, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

At other organizations: None

Shareholding: 5,273 shares, representing 0.01% of the Charter Capital

EXECUTIVE MANAGEMENT



Mr. Dang Van Viet
Quality Director

Date of Birth: October 5, 1965

Educational Background: Bachelor of Pharmacy

Professional Experience:

- ◆ May 1991 – May 1995: Staff, Dong Anh Pharmacy – Hanoi
 - ◆ June 1995 – 2001: Workshop Manager, Traphaco Joint Stock Company – Hanoi
 - ◆ 2002 – December 2003: Director, Traphaco Sapa Joint Stock Company
 - ◆ January 2004 – March 2007: Production Director, Nam Duoc Joint Stock Company – Hanoi
 - ◆ April 2007 – October 2012: Head of Quality Assurance Department, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
 - ◆ November 2012 – April 2015: Deputy Director, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
 - ◆ May 2015 – Present: Quality Director, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
- Current Positions at the listed organization: Quality Director
At other organizations: None
Shareholding: 141,008 shares, representing 0.392% of the Charter Capital



Mr. Pham Van Nam
Sales Director

Date of Birth: July 20, 1980

Educational Background: Bachelor of Pharmacy

Professional Experience:

- ◆ September 2002 – December 2011: Staff, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
 - ◆ January 2012 – November 2015: Branch Director – Ninh Giang, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
 - ◆ December 2015 – June 2018: Branch Director – Ninh Giang cum Deputy Head of Sales Operations Department
 - ◆ July 2018 – July 2020: Deputy Sales Director cum Branch Director – Ninh Giang
 - ◆ August 2020 – Present: Sales Director cum Branch Director – Ninh Giang, Hai Duong Pharmaceutical Medical Materials Joint Stock Company
- Current Positions at the listed organization: Sales Director
At other organizations: None

Shareholding: 19,478 shares, representing 0.054% of the Charter Capital



Mr. Chu Van Long
Chief Accountant

Date of Birth: February 6, 1966

Educational Background: Bachelor of Finance and Accounting (Major in Accounting)

Professional Experience:

◆ 1993 – 1997: Accountant, Hai Duong Pharmaceutical Medical Materials Company

◆ 1998 – 2003: Deputy Head of Accounting Department, Hai Duong Pharmaceutical Medical Materials Company

◆ 2004 – Present: Chief Accountant, Hai Duong Pharmaceutical Medical Materials Joint Stock Company

Current Positions at the listed organization: Chief Accountant

At other organizations: None

Shareholding: 129,629 shares, representing 0.36% of the Charter Capital

HUMAN RESOURCES

To meet operational requirements, the Company has recruited employees across various qualification levels..

Workforce Structure in 2025

Criteria	Number of Employees (2025)	Percentage (%)
University and Postgraduate	282	34.69%
College and Vocational Training	454	55.84%
Technical Workers (Intermediate Level)	41	5.04%
Unskilled Labor	36	4.43%
Total	813	100%

Labor Management:

The Company effectively manages working hours and primarily applies performance-based systems, including task-based and output-based assignments, to evaluate employee productivity.

Labor Policies:

During the year, the Company implemented various training programs, including: Sales skills training; Fire prevention and firefighting training; Occupational safety training; Professional training for managerial staff and laboratory personnel

Occupational health and safety activities are conducted regularly on an annual basis.

Income:

The average monthly income of employees reached VND 12,300,000 per person, representing an increase of VND 500,000, equivalent to a growth rate of 4.3% compared to the previous year.



FINANCIAL POSITION

No.	Indicator	2025	2024	Change (%)
1	Total Assets	952,550,231,804	646,386,356,355	47.37%
2	Net Revenue	683,713,520,353	665,001,708,794	2.81%
3	Operating Profit	68,328,814,621	48,644,815,248	40.46%
4	Other Income	1,436,746,884	2,143,693,425	-32.98%
5	Profit Before Tax	69,765,561,505	50,788,508,673	37.36%
6	Profit After Tax	55,703,190,202	40,608,780,696	37.17%
7	Earnings Per Share (EPS)	1,548	1,128	37.23%

No.	Indicator	2025	2024	Increase(+), Decrease(-)
1	Liquidity Ratios			
	Current Ratio (times)	1,57	1,83	0,26
	Quick Ratio (times)	0,89	1,15	0,26
2	Capital Structure Ratios			
	Liabilities / Total Assets (%)	47,24	29,72	17,52
	Liabilities / Equity (%)	89,25	42,29	46,96
3	Efficiency Ratios			
	Inventory Turnover Ratio (Cost of Goods Sold / Average Inventory)	3,2	3,9	-0,7
	Net Revenue / Total Assets (times)	0,718	0,972	-0,254
4	Profitability Ratios			
	Net Profit / Net Revenue (%)	8,15	6,11	2,04
	Net Profit / Equity (%)	11,07	8,94	2,13
	Net Profit / Total Assets (%)	5,84	6,28	-0,44
	Operating Profit / Net Revenue (%)	9,99	7,32	2,67

Liquidity

In 2025, the Company maintained a current ratio of 1.57 times, representing a decrease of 0.26 times (14.21%) compared to 2024. The quick ratio stood at 0.89 times, also declining by 0.26 times (22.61%) year-on-year.

Conclusion: The liquidity ratios slightly decreased compared to 2024. The main reason is that in 2025 the Company is implementing Phase 2 of the HDPHARMA factory project in Cam Thuong, resulting in higher payables to suppliers for machinery, equipment and construction at

year-end. However, these payables are supported by medium-term loans from BIDV Bank, ensuring timely payment when due. Therefore, with the above liquidity ratios, the Company is fully capable of meeting its short-term obligations as they fall due.


Capital Structure:

- The ratio of liabilities to total capital increased by 17.52%, as total capital in 2025 increased at a slower rate than liabilities. Specifically, total capital increased by 47.4%, while liabilities increased by 133.8% compared to 2024.
- The ratio of liabilities to equity also increased by 46.96%, as liabilities increased by 133.8%, while equity increased by only 10.8% compared to 2024.

Assessment: Both capital structure indicators increased compared to 2024. The main reason is the investment in the Cephalosporin injection and powder production line project, which has reached **95% of the total planned investment of VND 415 billion**. Machinery, equipment and factory construction have formed fixed assets, leading to a rapid increase in liabilities, mainly **VND 235 billion of medium-term loans** incurred in 2025. In addition, the Company increased raw material inventory at year-end to stabilize production amid global fluctuations in exchange rates and logistics costs, and increased customer prepayments for contract manufacturing, which also contributed to the increase in liabilities. Although these indicators increased, the Company continues to manage its capital effectively. The ratio of **liabilities to equity remains below 1**, indicating that the Company maintains financial independence in its operations and investment in the Phase 2 HDPHARMA factory project.

Operational Efficiency


The inventory turnover ratio in 2025 decreased by 0.7 times, equivalent to a decrease of 17.95% compared to 2024. The main reason is that average inventory increased by 16.9%, while cost of goods sold decreased by 3.53% compared to 2024. The increase in inventory is due to the Company's proactive purchase of imported raw materials to ensure stable production in 2026, avoiding shortages, exchange rate fluctuations, price increases and supply disruptions caused by prolonged conflicts in the Middle East and rising logistics costs. The ratio of net revenue to total assets decreased by 0.254 times, equivalent to a decrease of 8.47%, as net revenue in 2025 increased by 2.8%, while total assets increased by 47.36% compared to the previous year.



Indicators	2021	2022	2023	2024	2025
Current ratio	1.24	1.47	1.70	1.83	1.57
Liabilities / Equity	0.52	0.461	0.378	0.423	0.893
Net revenue / Total assets	1.10	1.062	1.067	0.972	0.718

Profitability Indicators:

Indicators	2021	2022	2023	2024	2025
Profit after tax / Net revenue (%)	4.77%	4.86%	5.13%	6.12%	8.15%
Profit after tax / Equity (%)	7.98%	7.60%	7.5%	8.94%	11.07%
Profit after tax / Total assets (%)	5.27%	5.20%	4.62%	6.28%	5.84%
Profit from operating activities / Net revenue (%)	5.55%	5.93%	6.29%	7.32%	9.994%



SHAREHOLDING STRUCTURE

Share Information

Total number of shares:	35.995.929 shares
Par value:	10.000 VND
Number of preferred shares:	0 shares
Number of ordinary shares:	35.995.929 shares
Number of outstanding shares:	35.995.929 shares
Number of freely transferable shares:	35.995.929 shares
Number of restricted shares:	0 shares

Shareholding Structure in 2025

Shareholder Structure by Ownership Type

No.	Category	Number of shareholders	Ratio (%)
1	Domestic shareholders		
	- Organizations	0	-
	- Individuals	438	99.939%
2	Foreign shareholders		
	- Organizations	2	0.012%
	- Individuals	3	0.046%
Total		443	100%

Shareholder Structure by Ownership Ratio

No.	Category	Number of shares	Ownership ratio / Charter capital
1	State shareholders	0	-
2	Founding shareholders	1,995,823	5.604%
3	Major shareholders	20,468,225	
	- Domestic	20,468,225	56.86%
	- Foreign	0	0%
4	Other shareholders	13,531,881	
	- Domestic	13,511,154	37.53%
	- Foreign	20,727	0.06%
TOTAL			100%

List of Major Shareholders:

Name of organization/individual	ID/Passport/Business Registration No.	Address	Number of shares	Ownership ratio
Nguyen Trung Viet	001069002861	Ciputra Urban Area, Tay Ho District, Hanoi	14,702,263	40.84%
Tran Mai Lan	001171004106	P506-L02 Nam Thang Long Urban Area, Xuan Dinh, Bac Tu Liem, Hanoi	5,765,962	16.02%

REPORT AND ASSESSMENT OF THE BOARD OF DIRECTORS

ASSESSMENT OF BUSINESS PERFORMANCE RESULTS FINANCIAL SITUATION IMPROVEMENTS IN MANAGEMENT POLICIES AND STRUCTURE FUTURE DEVELOPMENT PLAN

General Assessment:

We have passed through 2025, a year marked by significant changes both globally and domestically, with many unusual events. These include the U.S. Government increasing tariffs and applying reciprocal tariffs on import-export goods with most countries, unstable foreign exchange rates, global economic downturn, severe natural disasters, and regional conflicts in Eastern Europe between Russia and Ukraine as well as in the Middle East, which have caused global crises in economic, political, and environmental aspects. Vietnam, along with other Southeast Asian countries, has faced many challenges in maintaining political stability and macroeconomic balance. Enterprises have been heavily affected, facing extreme difficulties in all aspects of production and business activities, investment environment, and rising inflation. Many enterprises have had to suspend operations or proceed with dissolution, especially small and medium-sized enterprises. Hai Duong Pharmaceutical Medical Materials Joint Stock Company, as a medium-sized local enterprise, has been even more deeply affected. Therefore, 2025 continued to be a very challenging year for the Company in particular and for the Vietnamese pharmaceutical industry in general.

Market

In 2025, enterprises both within and outside the pharmaceutical sector continued to be affected by prolonged conflicts in the Middle East, severe natural disasters and floods, slow economic recovery, and changes in the business environment and models, leading to shifts in market share. The Company's key markets are the Central, Central Highlands, and Southern regions. In Hai Duong province, the Company is mainly strong in the ETC channel. Due to intense competition, the market share of the OTC channel for self-manufactured products in these potential regions has grown slowly and has not met expectations.

FINANCIAL SITUATION

Indicators	2025	2024	% change 2025/2024
Current assets	333,086,878,632	341,148,607,589	-2.36%
Cash and cash equivalents	44,408,946,125	31,419,168,182	41.34%
Short-term receivables	121,037,997,415	180,755,628,545	-33.04%
Inventories	143,634,151,611	127,909,053,084	12.29%
Other current assets	24,005,783,481	1,064,757,778	2154.58%
Non-current assets	619,463,353,172	305,237,748,766	102.94%
Net book value of fixed assets	471,482,526,434	277,938,572,145	69.64%
Long-term work in progress	142,391,317,925	24,432,507,459	482.79%
Long-term financial investments	1,835,000,000	0	-
Other non-current assets	3,754,508,813	2,866,669,162	30.97%
Total assets	952,550,231,804	646,386,356,355	47.37%
Total liabilities	449,236,682,497	192,108,895,710	133.84%
Short-term liabilities	212,182,405,640	186,108,895,749	14.01%
Long-term liabilities	237,054,276,857	6,018,294,961	3838.89%
Equity	503,313,549,307	454,259,165,645	10.80%
Total capital	952,550,231,804	646,386,356,355	47.37%

Asset Structure

In general, the Company's asset structure changed in 2025.

Current Assets

Total current assets in 2025 decreased by 2.36% compared to 2024. In detail, short-term receivables decreased by 33.04%, while cash and cash equivalents increased by 41.34%, inventories increased by 12.29%, and other current assets increased by 2,154.58%. Regarding the causes, the Company is currently implementing Phase 2 of the HDPHARMA factory construction project, which is in the final stage of completion. The project has reached approximately 95% of total workload, and contracts for machinery, equipment, and construction have largely been accepted,

finalized, and paid. Therefore, advances previously paid to suppliers since 2024 for the purchase of machinery and equipment have mostly decreased, specifically from VND 59.6 billion to VND 17.5 billion. Inventories increased as the Company has implemented a plan to stockpile raw materials to ensure stable production for 2026. Other current assets increased mainly due to input VAT of machinery, equipment, and construction for the project that has not yet been credited. In addition, trade receivables decreased from VND 118.2 billion to VND 109.8 billion. At the same time, in 2025, the Company made a provision for doubtful receivables of VND 6,614,233,874, an increase of VND 2,942,848,811 compared to 2024, in order to

ensure financial safety against potential credit risks.

Non-current Assets

Non-current assets in 2025 increased by 102.94% compared to 2024. The main reason is that Phase 2 of the HDPHARMA factory construction project in 2025 is in the final stage of completion, with total workload reaching approximately 95%. Contracts for machinery, equipment, and construction have largely been accepted, finalized, and paid, resulting in an increase

in the gross value of fixed assets by VND 214,349,445,578. At the same time, ongoing investment costs for the project under construction also increased, leading to a significant rise in long-term liabilities by 482.8% compared to 2024.

Equity

In 2025, the Company's equity increased by 10.79%, mainly due to the increase in retained earnings from business operations. Profit after tax in 2025 increased by 37.17% compared to 2024, contributing to the growth in equity.

IMPROVEMENTS IN MANAGEMENT POLICIES AND STRUCTURE

In 2025, the Company's leadership and management team effectively leveraged their organizational and management capabilities in line with market conditions. This has strengthened the newly established corporate culture, reshaped vision, direction, and strategy, and laid a solid foundation for the Company's future development. In terms of management, the Company implemented necessary measures such as stabilizing its workforce, reviewing and restructuring operational management processes across all activities, thereby enhancing stability and improving management efficiency. In 2025, the Company further maximized the use of its Enterprise Resource Planning (ERP) system in production planning, sales management, financial and accounting management, as well as human resource and payroll management. This has contributed to improving financial management, standardizing processes and procedures, and

strengthening the Company's overall financial governance framework. The Company continuously supplemented and improved its corporate governance documentation system based on updated legal regulations and actual operational conditions, ensuring timely adjustments to achieve optimal efficiency.



The Company's corporate governance complies with and meets the requirements of relevant regulations, including the Law on Enterprises No. 59/2020/QH14, the Law on Securities No. 54/2019/QH14, Decree No. 155/2020/ND-CP, Circular No. 116/2020/TT-BTC, Circular

No. 96/2020/TT-BTC on information disclosure dated November 16, 2020, and Circular No. 68/2024/TT-BTC dated September 18, 2024, which includes provisions on the roadmap for English information disclosure.

The Company ensures appropriate internal control and internal audit conditions. Its financial statements are prepared in compliance with applicable laws, fairly and accurately reflecting its business operations, and are audited by an audit firm approved by the Ministry of Finance.



The Board of Directors, Supervisory Board, and Board of Management possess sufficient competence and integrity, with no conflicts between personal interests and those of the Company. They have performed their roles and responsibilities effectively, contributing to the successful achievement of the Company's annual business plans.

The Company continuously strives to enhance its corporate governance practices, aiming to adopt best practices such as improving the effectiveness of the Board of Directors, strengthening the supervisory role of the Supervisory Board, and applying supportive solutions in management and business operations.

FUTURE DEVELOPMENT PLAN

In 2026, competition in the domestic pharmaceutical market will remain intense, directly affecting production and distribution. The ongoing conflict between Russia and Ukraine, economic tensions between Russia, the EU and the United States, as well as conflicts in the Middle East, have disrupted global supply chains, increased logistics costs, and, together with the imposition of reciprocal tariffs by the United States on most countries, have led to a serious global economic downturn, rising inflation and prices. These factors will pose significant challenges for the Company. The Company's Board of Management will continue to accurately assess the capabilities of its production and business system, as well as evaluate competitors, in order to establish appropriate orientations and make timely adjustments in line with market conditions:

Adjust customer policies to better align with market conditions.

Continuously improve policies supporting production and business activities.

Functional departments, contract manufacturing customer department, business division, especially the customer service department, shall enhance responsiveness, promptly receive information, and effectively meet customer needs.

Focus on improving policies related to research and development, labor norms, and wage structures for each product.

Continue to implement and apply quality management systems in accordance with GMP, GLP, GSP, ISO 9001:2015 and ISO 13485:2016 standards.

Persist in implementing total quality management policies to build customer trust.

Focus on research and development of strategic, high-value products to build HDPHARMA's brand.

Invest in additional machinery and equipment to enhance production capacity and product quality.

Improve workforce skills and promote innovation and continuous improvement.

Ensure employees strictly follow established procedures, standards, and corporate culture guidelines.

Put into operation the production line for tablets and effervescent granules free from Beta-lactam antibiotics, meeting EU-GMP standards.

Effectively conduct GMP re-validation for existing pharmaceutical production lines meeting GMP-WHO standards and health supplement production when due.

Business Policy:

Continuously improve and effectively implement the principle of “customer-centric approach.” The business system serves as the Company’s direct interface with customers and acts as a bridge to deliver products to end users. In the context of increasing market competition, the Business Division recognizes the need for continuous improvement across the entire system to better meet and satisfy customer demands. Therefore, policies must be continuously refined to provide the best customer service and deliver the highest overall quality, from products to supply services.

In 2026, the Business Division will further refine specific policies as follows:

- ✓ Compensation and incentive policies: Ensure stable income and create motivation for sales personnel to achieve sales targets.
- ✓ Sales assignment policies: Establish appropriate sales allocation mechanisms for effective implementation across departments.
- ✓ Sales and marketing policies: Align with products and market conditions.
- ✓ Distribution system: Complete the nationwide distribution network, with Hanoi Branch, Central Branch in Da Nang, Ho Chi Minh City Branch, and Can Tho Branch serving as core hubs of the new distribution system.

Business Operations

Strive to achieve total sales revenue of VND 840 billion in 2026.

Professionalize the tendering team, aiming to expand Hai Duong-manufactured products beyond the province through both direct participation in bidding and joint ventures with partners in each distribution area.

Complete the OTC sales system to strengthen the Hai Duong brand, build customer habits, and expand HDPHARMA products nationwide.

Invest in provincial sales systems and implement optimal sales policies to retain distributors, agents, and collaborators. **Công tác hoàn thiện hệ thống bán hàng sản xuất**

OTC Channel:

- ✓ Rebuild and strengthen the entire personnel system from regional managers to medical representatives nationwide in line with the approved business strategy.
- ✓ Select distributors and closely supervise medical representatives and distributors to ensure effective market coverage and strict management of personnel, inventory, and receivables.
- ✓ Expand the sales network and increase market coverage to boost market share and sales revenue.

- ✓ Improve average monthly sales performance per medical representative according to targets.
- ✓ Accelerate the launch of new products to bring them to market quickly and effectively.
- ✓ Increase product presence at points of sale and boost sales of successfully introduced products.
- ✓ Maximize the use of available tools and sales policies to enhance management efficiency and drive revenue growth.
- ✓ Implement appropriate solutions to expand distribution into supermarket systems, nationwide pharmacy chains, online sales channels, and e-commerce platforms.
- ✓ **ETC Channel:**
- ✓ Recruit qualified personnel with a professional attitude and long-term commitment to the Company.
- ✓ Maintain workforce stability, expand into remote areas, and strengthen relationships with hospitals and government authorities. Consolidate presence in provinces such as **Vinh Phuc, Thai Nguyen, Phu Tho, Son La, Tuyen Quang, Ha Giang, Dien Bien, Hoa Binh**, as well as regions in the South and Central areas where the Company has not yet participated in tenders.
- ✓ Develop detailed plans for product portfolios and bidding volumes for each product in each locality where tenders are expected in 2026, ensuring growth in both volume and value of successful bids compared to the previous year. Based on this, propose bidding prices, monitor results, and closely implement sales in line with awarded tenders.
- ✓ Actively participate in tenders for products manufactured on **EU-GMP compliant production lines** in 2026 and subsequent years.
- ✓ Enhance the effectiveness of **semi-tender sales** to clinics providing insured medical services nationwide.

Promote the introduction and sales of new products registered and launched by the Product Development Council, including products with improved design and quality.

Branches shall coordinate with the Business and Marketing Departments to implement promotional programs tailored to customer preferences.

Regularly organize customer seminars and conferences across provinces.

The Business Division shall coordinate with other departments (Marketing, Quality Assurance, etc.) to provide professional training for regional managers and medical representatives, and develop team-based and regional working models in 2026.

Strive to achieve a production output value of VND 518 billion in 2026, while maintaining stable product quality and continuously improving production organization to ensure timely supply to customers.

ASSESSMENT OF THE BOARD OF DIRECTORS ON THE COMPANY'S OPERATIONS

ASSESSMENT OF THE BOARD OF DIRECTORS ON ALL ASPECTS OF THE COMPANY'S OPERATIONS

ORIENTATIONS AND PLANS OF THE BOARD OF DIRECTORS ASSESSMENT OF THE BOARD OF DIRECTORS ON THE BOARD OF MANAGEMENT

The year 2025 remained a challenging year not only for the Company but also for the entire Vietnamese pharmaceutical industry. The market faced intense competition with the participation of foreign pharmaceutical corporations, the saturation of health supplement products, stricter regulatory requirements, and the sharp increase in raw material prices in the pharmaceutical sector. In addition, severe natural disasters and floods in the last six months of the year, prolonged conflicts in the Middle East, the imposition of reciprocal tariff policies by the United States, rising inflation, global economic instability, disruptions in supply chains and logistics, as well as changes in consumer behavior, all created significant challenges. However, with the strong efforts of the Board of Directors and all employees, the Company successfully overcame these difficulties and achieved encouraging results in 2025:

- Net revenue increased by 2.81% compared to 2024.
- Profit after tax increased by 37.17%, exceeding the target set by the 2025 General Meeting of Shareholders by 46.58%.
- Production output value increased by 9.2% compared to 2024.
- Existing resources were utilized effectively, and employment and income for more than 800 employees were maintained stably and improved.

Project Implementation:

The Board of Directors and the Board of Management are finalizing the last stages of investment and construction for Phase 2 of the HDPHARMA EU factory project, namely: "Construction of a production line for injectable powder and Beta-lactam tablets of the Cephalosporin antibiotic group meeting EU-GMP standards" in Cam Thuong, in accordance with the resolution of the General Meeting of Shareholders, and the project is expected to be completed in 2026.

Images of selected advanced technology equipment



EU-standard packaging machine





Số N: 080001
CÔNG
CỐP
DUỐC
HÀ
THÀNH Đ

Automatic eye drop filling machine



Injectable drug production line



Final mixing machine – EU-GMP compliant

ORIENTATIONS AND STRATEGIC PLANS OF THE BOARD OF DIRECTORS

1. Vision and Mission

Striving to become a symbol and one of the leading brands in Vietnam in the field of community healthcare. HDPHARMA is committed to delivering the highest overall quality and best satisfying customers' needs for a healthy life.

2. Objectives

- Continue to implement and apply quality management systems in accordance with **GMP, GLP, GSP, and applicable ISO standards.**
- Invest in additional machinery and equipment to enhance production capacity and product quality; improve workforce skills and promote innovation.
- Aim to become one of the leading enterprises in the Vietnamese pharmaceutical industry.
- Improve production and develop a modern manufacturing system.
- Complete the OTC sales system to strengthen the Hai Duong brand, build customer habits, and expand HDPHARMA products nationwide, positioning the Company's brands among leading product groups.
- Maximize market share of self-manufactured products.
- Expand market coverage and develop market share for the Company's products.
- Build HDPHARMA into a company managed under modern standards with standardized processes and procedures.
- Develop human resources in line with the orientation: aspiration, modernity, enthusiasm, and professionalism.
- Establish joint ventures and partnerships with major pharmaceutical companies for production

and business cooperation, including joint development of production lines.

3. Strategic Pillars

The Company's strategy is built on three main directions:

3.1. Developing a modern production system

- Focus on quality as the core objective, centered on **EU-GMP standards**.
- Prioritize **key production lines instead of key products**.
- Strengthen research and development as a key factor affecting product quality.
- Emphasize quality as a critical factor due to increasing regulatory requirements and market expectations.

3.2. **Building a professional and modern business system:** Develop a nationwide distribution network and expand export markets.

3.3. **Establishing a marketing-oriented approach:** Apply marketing orientation across all Company activities.

4. Các kế hoạch cụ thể

Strive to achieve a production output value of **VND 518 billion in 2026** with stable product quality.

Target total sales revenue of **VND 840 billion in 2026**.

- For Plant No. 1 (102 Chi Lang):

- Continue to maximize utilization of existing production lines.
- Replace the injectable production line with a modern, higher-capacity system.
- Invest in BFS production lines for ophthalmic, nasal, and inhalation products.
- Consider investment in liquid oral formulation production lines.

- For HDPHARMA EU Plant:

• Continue implementation of Phase 2 and Phase 3 of the project:

+ Complete validation and commence operation of two production lines: "Production lines for injectable powder and Beta-lactam tablets of the Cephalosporin antibiotic group meeting EU-GMP standards" in 2026.

+ Immediately proceed with Phase 3, including the construction of the 4D office building and the remaining three EU-GMP production lines in Building 4B, in accordance with the approved master plan, with basic completion of factory and office infrastructure expected within two years.

- Maximize the advantages of EU-GMP compliant production lines.
- Strengthen export activities.
- Cooperate with major global partners to achieve breakthrough revenue growth.
- Develop human resources.
- Improve, modernize, and expand the business system.

ĐÁNH GIÁ CỦA HỘI ĐỒNG QUẢN TRỊ VỀ BAN GIÁM ĐỐC

With a strong sense of responsibility towards shareholders, employees, and the sustainable development of the Company, the Board of Directors has exercised supervision and direction over the General Director and other management departments in the daily operation of the Company's business activities in compliance with applicable laws, the Company's Charter, and resolutions of the General Meeting of Shareholders and the Board of Directors. At the same time, the assigned rights and duties have been performed honestly and prudently to ensure the maximum legitimate interests of the Company and its shareholders.

The Board of Directors' supervisory activities over the General Director are carried out through monthly reports of the Board's subcommittees and through comprehensive, timely, and detailed reports from the General Director regarding implementation progress, operational directions, and arising difficulties and challenges at both regular monthly and ad-hoc Board meetings. Through these mechanisms, the Board is able to closely monitor the Company's situation and make timely and appropriate decisions to ensure smooth and effective business operations.

In its executive role, the Board of Management has demonstrated a high level of responsibility, professional competence, and integrity. Members are well-trained, knowledgeable in their respective areas of responsibility, and possess extensive experience in managing and operating the Company. The Board of Management complies with the monthly reporting regime on business performance, and has effectively implemented the strategic directions of the Board of Directors and the resolutions of the General Meeting of Shareholders in accordance with established plans.

The Board of Directors agrees with the report of the Board of Management on the Company's business performance in 2025. Key indicators such as tax obligations, employment and income of employees, shareholders' interests, investment in production development, environmental protection, and fulfillment of social responsibilities have been fully reported and accurately reflect the Company's actual situation. However, in 2025, the distribution system has not yet been fully completed. The impact

ANNUAL REPORT 2025 HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JOINT STOCK COMPANY



BOARD OF DIRECTORS – SUPERVISORY BOARD
RESOLUTIONS OF THE BOARD OF DIRECTORS DURING THE YEAR
REMUNERATION, BONUSES, BENEFITS AND SHARE TRANSACTIONS
OF INTERNAL SHAREHOLDERS
BOARD OF DIRECTORS

Members and Structure of the Board of Directors

Full name	Position	Number of shares held
Nguyen Trung Viet	Chairman of the Board of Directors	14,702,263 shares
Nguyen Thi Tu Anh	Member of the Board of Directors cum General Director	1,363,191 shares
Tran Phuc Duong	Member of the Board of Directors	1,461,926 shares

Subcommittees under the Board of Directors

Subcommittee	Responsibilities	Performance evaluation
Reward and Discipline Committee	Participate in reviewing and analyzing before the Chairman decides on commendation forms; the General Director decides on disciplinary actions for employees.	Performed assigned roles and responsibilities effectively.
Scientific and Technical Committee	Advise the Board of Directors on research, application, and development strategies; review and recognize research projects and improvement initiatives.	Performed assigned roles and responsibilities effectively.
Inventory Committee	Determine the actual value of assets and inventories at reporting periods or re-evaluate assets at a specific time.	Performed assigned roles and responsibilities effectively.
Liquidation Committee	Assist the Board of Directors in identifying assets and goods that are no longer usable for revaluation or disposal.	Performed assigned roles and responsibilities effectively.
Occupational Safety Committee	Advise the General Director and coordinate in developing management regulations, action programs, labor protection plans, occupational safety, fire prevention, environmental protection, and improvement of working conditions; prevent occupational accidents and diseases in compliance with regulations.	Performed assigned roles and responsibilities effectively.
Acceptance Committee	Advise the Board of Directors, inspect and verify the quality and quantity of fixed assets, machinery, equipment, and completed construction works in accordance with approved technical standards.	Performed assigned roles and responsibilities effectively.

Activities of the Board of Directors:

In 2024, the Board of Directors held 11 regular meetings to directly supervise, inspect, and evaluate the Company's business operations. The Board made decisions on both regular and ad-hoc matters within its authority, including: approval of business plans, investment projects, borrowing plans, quarterly and annual financial statements, and organizational restructuring. All

meetings were conducted in compliance with applicable laws, the Company's Charter, and the Board of Directors' operating regulations. Minutes were prepared for each meeting.

No.	Board member	Position	Number of meetings attended	Attendance rate	Reason for absence
1	Mr. Nguyen Trung Viet	Chairman of the Board of Directors	14	100%	
2	Mr. Tran Phuc Duong	Member of the Board of Directors	14	100%	
3	Ms. Nguyen Thi Tu Anh	Member of the Board of Directors cum General Director	14	100%	

Resolutions of the Board of Directors in 2025:

No.	Resolution No.	Date	Contents	Approval rate
1	19/BB-NQ/HĐQT	10/01/2025	- Formulation and approval of the 2025 business and production plan: + Production output value plan: VND 476 billion + Sales revenue plan: VND 840 billion - Development and implementation of the Company's strategy for 2025 and subsequent years - Establishment of the organizing subcommittee for the 2025 Annual General Meeting of Shareholders and preparation of related documents and legal procedures in accordance with regulations and the Company's Charter (expected on April 3, 2025) - Selection of the auditor for 2024 financial statements - Continued implementation and completion of Phase 2 of the HDPHARMA factory project in Cam Thuong: "EU-GMP pharmaceutical production line for Cephalosporin antibiotics in tablet and powder dosage forms"	3/3
2	20/BB-NQ/HĐQT	10/03/2025	- Approval of audited financial statements and business results for 2024 - Announcement of the plan to organize the 2025 Annual General Meeting of Shareholders	3/3
3	20+21/BB-NQ/HĐQT	10/03/2025	- Approval of working capital credit limit of VND 50 billion at VietinBank Hai Duong Branch	3/3
4	23/BB-NQ/HĐQT	01/03/2025	- Approval of documents, reports submitted to the General Meeting of Shareholders and organization of the 2025 AGM	3/3

5	24+25/BB -NQ/HĐQT	03/04/2025	- Establishment of a wholly-owned subsidiary - Name: Hai Duong Pharmaceutical Medical Materials Co., Ltd., charter capital VND 5 billion	3/3
6	28+29/BB -NQ/HĐQT	04/04/2025	- Implementation of the plan to issue shares to increase charter capital from equity sources as approved by the 2025 AGM	3/3
7	30+31/BB -NQ/HĐQT	28/04/2025	- Adjustment of project scale and extension of implementation timeline for the project: “Pharmaceutical manufacturing plant for injectables, tablets and traditional medicines meeting GMP standards” - Approval of the record date for shareholders entitled to receive bonus shares from equity - Record date: May 15, 2025 - Approval of Q1/2025 financial statements	3/3
8	32+33/BB -NQ/HĐQT	28/05/2025	- Increase in charter capital from VND 279,473,170,000 to VND 359,959,290,000 through share issuance from equity - Amendment of Article 1, Appendix 1 of the Company’s Charter - Amendment of Enterprise Registration Certificate in line with new charter capital - Additional securities registration and trading registration for 8,048,827 newly issued shares	3/3
9	34/BB- NQ/HĐQT	10/07/2025	- Change of the Company’s address in accordance with new administrative boundary adjustments issued by the State	3/3
10	35+36/BB -NQ/HĐQT	11/08/2025	- Approval of reviewed financial statements by Vietnam Auditing and Valuation Co., Ltd. - Assessment of business performance in the first 6 months and approval of working capital loan and L/C issuance at BIDV Hai Duong Branch with a credit limit of VND 100 billion	3/3
11	37+38/BB -NQ/HĐQT	20/08/2025	- Dissolution and termination of operation of Central Pharmacy Branch (Tax code: 0800011018- 002), originally issued on August 31, 1998 by Hai Duong DPI	3/3
12	39+40/BB -NQ/HĐQT	28/08/2025	- Loan arrangement and use of collateral at BIDV Hai Duong Branch - Supplement of medium- term capital for Phase 2 of the EU-GMP pharmaceutical manufacturing plant project	3/3
13	41/BB- NQ/HĐQT	28/10/2025	- Approval of notarized land use right transfer contracts for plots L09-53 and L09-54 under KITA INVEST project - Authorization for Ms. Nguyen Thi Tu Anh – Board Member and General Director to sign related documents	3/3
14	42/BB- NQ/HĐQT	12/11/2025	- Approval of working capital loan, guarantee issuance, and L/C opening at VIB Quang Ninh Branch with a credit limit of VND 60 billion	3/3

Activities of Independent Members of the Board of Directors

Independent members of the Board of Directors, although not directly involved in the Company's executive management, still perform the function of supervising the activities of the Executive Board and the overall operations of the Company.

In 2025, the independent Board member fulfilled supervisory duties fully and appropriately, requested the review of reports, evaluated arising issues, and participated in all Board meetings. Through this, supervision was carried out regularly, continuously, and objectively.

The independent member of the Board of Directors is Mr. Tran Phuc Duong. In 2025, he participated together with other Board members in resolving matters subject to Board approval.

SUPERVISORY BOARD

Members and Structure of the Supervisory Board

Full name	Position	Number of shares held
Pham Thi Thuy	Head of Supervisory Board	320,260 shares
Tran Kim Cuong	Member	185,664 shares
Nguyen Thi Huong Lan	Member	5,273 shares

Activities of the Supervisory Board

The Supervisory Board consists of **one Head and two members**, all of whom performed their duties in accordance with the Supervisory Board's operating regulations.

During the year, the Supervisory Board coordinated and worked directly with the Board of Management to monitor the Company's operations and contributed opinions to address difficulties arising in the management and operation of business activities.

The Supervisory Board closely monitored the Company's operational performance, development orientation, and the implementation of resolutions of the 2025 Annual General Meeting of Shareholders. It reviewed reports on management and executive activities, quarterly business performance reports, and the audited financial statements for 2025.

The Supervisory Board also received information on decisions of the Board of Directors, reports on tasks, plans, and implementation measures; at the same time, it reviewed and monitored the direction and execution of activities of the Board of Directors as well as the performance of duties by the Executive Board.

Supervisory Results on the Activities of the Board of Directors and the Executive Board in Implementing the Resolutions of the 2025 Annual General Meeting of Shareholders

In 2025, the Supervisory Board did not receive any complaints from shareholders regarding the Company's business operations or the management of the Board of Directors and the Executive Board. Reports of the Board of Directors and the Executive Board fully and accurately reflected the Company's operations. All documents and resolutions issued by the Board of Directors complied with the Law on Enterprises and the Company's Charter.

- Implementation of Business and Production Targets

+ **Total revenue:** VND 689,532,822,613, achieving 83.08% of the plan, up 3.21% compared to 2024 (equivalent to an increase of VND 21,476,634,371).

+ **Total production output value:** VND 382,452,964,474, achieving 80.35% of the plan, up 9.23% compared to 2024 (equivalent to an increase of VND 32,330,914,838).

+ **Profit after tax:** VND 55,703,190,202, reaching 146.59% of the plan approved by the General Meeting of Shareholders, up 37.17% compared to 2024 (equivalent to an increase of VND 15,094,409,506).

- **Basic earnings per share (EPS) in 2025:** VND 1,548/share.

- In 2025, the Company implemented a share issuance to increase charter capital from equity sources at a rate of **28.8%**, equivalent to **VND 80,486,120,000** (8,048,612 shares). The Company also completed securities depository registration for these shares to ensure shareholders' rights in trading on the UPCOM market.

- The Company paid **2024 cash dividends at a rate of 2.2%**, totaling **VND 6,148,409,740**, in accordance with the AGM resolution.

- Funds were appropriated in accordance with the profit distribution plan approved by the General Meeting of Shareholders.

- The Company selected **Vietnam Auditing and Valuation Co., Ltd.** to conduct the semi-annual review and full audit of the 2025 financial statements in compliance with the Law on Securities and regulations of the State Securities Commission.

- Remuneration paid to the Board of Directors was **3%**, and to the Supervisory Board **1%** of profit after corporate income tax, in accordance with the Company's Charter and AGM resolutions.

- **Charter capital as of the end of 2025:** VND 359,959,290,000, an increase of VND 80,486,120,000 (equivalent to 28.8%) compared to 2024, resulting from the share issuance from equity sources.

- In 2025, the Company completed approximately 95% of construction, installation of machinery and production lines for Phase 2 of the HDPHARMA EU factory project (expected completion by the end of 2026), while continuing preparations for Phase 3 of the project.

REMUNERATION, BONUSES AND BENEFITS

Full name Board of Directors (total)	Position	Remuneration (VND)		
		1,501,190,400	554,911,767	2,056,102,167
Nguyen Trung Viet	Chairman	500,396,800	131,227,249	631,624,049
Nguyen Thi Tu Anh	Member	500,396,800	423,684,518	924,081,318
Tran Phuc Duong	Member	500,396,800	0	500,396,800
Supervisory Board (total)		500,397,000	707,602,631	1,207,999,631
Pham Thi Thuy	Head	166,799,000	211,532,318	378,331,318
Tran Kim Cuong	Member	166,799,000	183,240,538	350,039,538
Nguyen Thi Huong Lan	Member	166,799,000	312,829,775	479,628,775
Total		2,001,587,400	1,262,514,398	3,264,101,798
Full name	Position	Remuneration (VND)	Salary (VND)	Total income (VND)

SHARE TRANSACTIONS OF INTERNAL SHAREHOLDERS AND RELATED PERSONS

(Changes due to dividend share issuance and additional purchases)

Name Nguyen Trung Viet	Relationship	Shares at beginning		%	
		11,414,801	40.84%	14,702,263	40.84%
Tran Mai Lan	Wife of Chairman	4,579,940	16.39%	5,765,962	16.02%
Nguyen Thi Tu Anh		1,123,823	4.02%	1,363,191	3.79%
Vu Van Xuyen	Husband of General Director	639,900	2.29%	783,918	2.18%
Vu Hien Minh Anh	Daughter of General Director	13,300	0.05%	89,160	0.25%
Nguyen Trung Nam	Younger brother of General Director	420,617	1.51%	541,754	1.51%
Tran Phuc Duong		1,135,036	4.06%	1,461,926	4.06%
Pham Thi Thuy		237,085	0.85%	324,260	0.90%
Tran Khanh Huyen	Daughter of Head of Supervisory Board	9,900	0.04%	14,793	0.04%
Pham Thi Lan	Younger sister of Head of Supervisory Board	4,943	0.02%	6,282	0.02%

Tran Kim Cuong		145,780	0.52%	185,664	0.52%
Tran Van Oanh	Father of Mr. Tran Kim Cuong	274,760	0.98%	353,890	0.98%
Pham Thi Nhan	Mother of Mr. Tran Kim Cuong	75,667	0.27%	97,459	0.27%
Tran Van Minh	Younger brother of Mr. Tran Kim Cuong	37,831	0.13%	48,726	0.13%
Chu Van Long		100,644	0.36%	129,629	0.36%
Ho Thi Ngoc Thanh	Wife of Mr. Chu Van Long	67,354	0.24%	86,751	0.24%
Nguyen Thi Huong Lan		3,894	0.01%	5,273	0.01%
Name	Relationship	Shares at beginning	%	Shares at end	%

SUSTAINABILITY REPORT

2025



GENERAL INFORMATION ON THE SUSTAINABILITY REPORT

Report Introduction

The Sustainability Report of Hai Duong Pharmaceutical Medical Materials Joint Stock Company is integrated into the Annual Report to avoid duplication, ensuring concise, high-quality information for shareholders and relevant stakeholders. The purpose of the Sustainability Report is to provide information on the Company's development orientation and policies related to environmental, social, community, employee matters, and other stakeholders.

Objectives

The Sustainability Report is an important part of the Annual Report, helping investors, shareholders, and stakeholders access information on the Company's development strategy and business operations from a sustainability perspective. The report summarizes and evaluates the Company's sustainability activities.

Methodology for Determining Report Content

The report is prepared based on the **Global Reporting Initiative (GRI) Standards – G4 version**, in accordance with the "Core" option, and the guidelines for annual reports under **Circular No. 96/2020/TT-BTC** of the Ministry of Finance. Based on the Company's vision, development orientation, and business strategy, the report identifies key material issues that significantly impact economic, social, and environmental aspects.

Reporting Period

The report covers the fiscal year 2025, from January 1, 2025 to December 31, 2025.

Since 2016, the Company has prepared Sustainability Reports annually and disclosed them together with the Annual Report in compliance with Circular No. 96/2020/TT-BTC and Circular No. 68/TT-BTC of the Ministry of Finance.

Reporting Scope

This report covers the operations of Hai Duong Pharmaceutical Medical Materials Joint Stock Company and its affiliated units in the pharmaceutical sector within the territory of Vietnam.

Report Assurance

The Company refers to and applies both domestic and international standards in disclosing information and data in the report.

Certain operational data presented in the report are verified by third parties to ensure accuracy, reliability, and integrity. Specifically:

- Financial information is audited by **Vietnam Auditing and Valuation Co., Ltd.**
- Certain key certifications in the pharmaceutical field

Contact Information

For any inquiries, please contact:


Hai Duong Pharmaceutical Medical Materials Joint Stock Company
Address: No. 102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam
Tel: 0220.3853.848
Fax: 0220.3853.848
Email: info@hdpharma.vn

ENERGY CONSUMPTION

The Company has been expanding its operations in recent years, leading to an increase in energy consumption.

Currently, electricity is supplied by **Hai Duong Power Company Limited**. Electricity consumption over the years is as follows:

Year	Consumption (kWh)
2022	5,063,287
2023	5,873,822
2024	6,487,113
2025	7,273,460



Along with investments in machinery and the operation of modern production lines, the Company has effectively implemented energy-saving policies.

To enhance awareness among all employees regarding energy conservation both at the workplace and at home, the Company has introduced various measures and regulations, including:

- Switching off electrical equipment when not in use after working hours
- Maximizing the use of natural lighting and ventilation
- Using air conditioning only when necessary
- Setting cooling temperatures at **25°C or above**
- When upgrading or installing new equipment, prioritizing energy-efficient devices or those with energy-saving labels in accordance with regulations

WATER CONSUMPTION

Water is supplied by Hai Duong Clean Water One Member Co., Ltd. The Company's water consumption is as follows:

Year	Volume (m ³)	Cost (VND)
2024	163,322	2,486,572,375
2025	179,640	2,735,012,475

The Company consistently emphasizes water-saving policies and promotes awareness among all employees regarding efficient water use. Employees are encouraged to practice water conservation not only at the workplace but also in their daily lives and within the community.



2025年11月

EMPLOYEE-RELATED POLICIES

No	Criteria	Number of employees (2025)	Ratio 2025 (%)
I	By Education Level		
1	University and Postgraduate	282	34,69%
2	College and Vocational Intermediate	454	55,84%
3	Primary Vocational and Technical Workers	41	5,04%
4	Unskilled Workers	36	4,43%
II	By Employment Type		
1	Direct labor	570	70,11%
2	Indirect labor	243	29,89%
III	By Gender		
1	Male	342	42,07%
2	Female	471	57,93%
IV	By Position		
1	Management	81	9,96%
2	Office staff & Business division	502	61,75%
3	Workers	230	28,29%



The Company's management recognizes that human resources are the key factor determining the success or failure of the business. In recent years, the Company has made continuous efforts to build a positive working environment, ensure employees' rights and benefits, and strictly comply with labor laws and regulations. As the Company is headquartered in Hai Duong Province rather than a major city or centrally governed municipality, recruitment has faced certain challenges. Therefore, the Company has consistently implemented attractive policies and incentives to attract and retain employees, particularly experienced personnel and those with long-term commitment to the Company. Employees working at the Company are entitled to full participation in all statutory insurance schemes in accordance with State regulations. In addition, the Company provides various benefits, including: Bonuses on public holidays and Tet (Lunar New Year), Birthday gifts or cash allowances, Mobile phone allowances for managers and certain staff, Additional support policies for female employees during maternity and childcare periods (e.g., childbirth allowances, reduced working hours, etc.), Periodic health check-ups

Recognition and rewards for employees' children with outstanding academic achievements, Gifts for children on International Children's Day and Mid-Autumn Festival, Support and encouragement for employees facing difficult circumstances



During public holidays and special occasions, the Company collaborates with internal organizations to arrange: Sports, cultural and artistic activities, Company trips and outings for employees,



Occupational Health and Safety Management

The Company has established an **Occupational Safety and Hygiene Council**, which is responsible for developing annual labor protection plans in line with the specific conditions of each period.

A safety and hygiene network has been implemented down to each production team, with employees participating in training programs organized by the Company and the Department of Labor, Invalids and Social Affairs.

The Company strictly complies with all regulations and standards on **fire prevention and firefighting (PCCC)** during production. Flammable and explosive

materials are stored separately in designated areas.

Storage facilities and containers are designed with appropriate safety features, including temperature monitoring systems and fire alarm systems. A comprehensive fire protection system has been installed, including water supply pipelines reaching all production workshops, along with fire hydrants located near production areas and warehouses. The Company has established a dedicated **fire prevention and firefighting team**, responsible for ensuring safety across all operational areas. This team receives regular training to maintain readiness. All workers operating in high-risk areas are properly trained in fire safety procedures.

In addition, the Company has developed fire prevention and firefighting plans that have been reviewed and approved by the **Fire Prevention and Fighting Police Department of Hai Duong Province** prior to construction and operation.

Fire hydrants are evenly distributed across residential and operational areas, along transportation routes and facility corridors. Firefighting equipment such as CO₂ extinguishers and foam extinguishers are strategically placed at easily accessible locations within the facilities to ensure prompt response in case of emergencies.

Environmental Management Activities

The Company maintains the operation of an **Environmental Management Team**, which is responsible for overseeing environmental management across all Company areas. The team is tasked with inspecting, monitoring, and encouraging employees to maintain environmental hygiene, as well as identifying and supervising potential environmental risks. It also develops periodic plans for environmental monitoring within production areas and surrounding zones, and is responsible for handling other environment-related matters.

Training and Development Activities

Annually, based on operational plans and actual needs of departments, the Company organizes

training programs to enhance employees' professional qualifications, including: Training on **GMP standards**, occupational health and safety, and fire prevention and firefighting

- **Internal Training:** Internal training programs are conducted directly by the Company's management staff.

Participants include employees working in departments, divisions, and workshops directly involved in production activities.

- The Company assigns staff from relevant departments to participate in specialized training programs organized by competent authorities and professional organizations in various fields, including: quality control, quality assurance, research and development, accounting, payroll, insurance, and occupational safety.

- The Company also invites external organizations to deliver training programs for employees, such as: Sales skills training, Advanced occupational health and safety training



Community Responsibility

Alongside its business operations, with the support and direction of the Party Committee, the Board of Directors, and the Company's Management, the Company has actively contributed to social welfare and community development in recent years.

- Providing charitable donations and humanitarian support to social organizations such as the **Youth Union** and the **Hai Phong Labor Federation**
- Supporting poor households and families in difficult circumstances
- Collaborating with healthcare units in Hai Duong to organize **free medical examinations and medicine distribution** for disadvantaged families and policy beneficiaries; supporting hospitals with medical equipment and supplies
- Contributing fully to social funds such as the **Fund for the Poor** and the **Agent Orange Victims Fund**
- Sponsoring and providing monthly financial support for **two orphaned children in extremely difficult circumstances** in Thanh Dong Ward, Hai Phong City, until they reach 18 years old
- Coordinating with local authorities to fund the construction of **charity houses** for underprivileged households in Thanh Dong Ward



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS
JOINT STOCK COMPANY**

SEPARATE FINANCIAL STATEMENTS

for fiscal year ended 31/12/2025

(Audited)

CONTENTS

	Page
Report of the Board of General Director	02-03
Independent Auditors' Report	04-05
Audited Separate Financial statements	
Separate Statement of Financial position	06-07
Separate Statement of Comprehensive income	08
Separate Statement of Cash flows	09-10
Notes to the separate financial statements	11-35

HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JOINT STOCK COMPANY
M.B.D.N. O.
P.S.

REPORT OF THE BOARD OF GENERAL DIRECTOR

The Board of General Directors of Hai Duong Pharmaceutical Medical Materials Joint Stock Company (the "Company") presents its report and the Company's Separate Financial statements for fiscal year ended 31/12/2025.

Company

Hai Duong Pharmaceutical Medical Materials Joint Stock Company.

Business Registration Certificate No.

0800011018, registered for the first time on 04/04/2003, registered for the 23rd on 16/07/2025
Issued by the Department of Finance of Hai Phong City.

Head office

No. 102, Chi Lang Street, Thanh Dong Ward, Hai Phong City .

Board of management

The Board of Management in the fiscal year and to the reporting date are:

Mr. Nguyen Trung Viet	Chairman of the Board of Directors
Mrs. Nguyen Thi Tu Anh	Member
Mr. Tran Phuc Duong	Member

Board of General Director

The Board of General Directors in the fiscal year and to the reporting date are:

Mrs. Nguyen Thi Tu Anh	General Director
Mr. Dang Van Viet	Quality Manager
Mr. Pham Van Nam	Sales Director
Mr. Chu Van Long	Chief Accountant

Board of Supervision

The members of the Board of Supervision in the fiscal year and to the reporting date are:

Mrs. Pham Thi Thuy	Head of Committee
Mrs. Nguyen Thi Huong Lan	Member
Mr. Tran Kim Cuong	Member

Legal representative

Mr. Nguyen Trung Viet	Chairman of the Board of Directors
Mrs. Nguyen Thi Tu Anh	General Director

Auditors

Vietnam Auditing and Valuation Company Limited (AVA).

Responsibilities of The Board of General Director for Separate Financial statements

The Board of General Directors is responsible for the Separate Financial statements of each financial year which give a true and fair view of the state of affairs of the Company and of its operation results and cash flows for the period. In preparing those Separate Financial statements, the Board of General Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of General Directors is responsible for ensuring that proper accounting records are kept which disclosed, with reasonable accuracy at any time, the financial position of Company and to ensure that the accounting records comply with the registered accounting system. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

We, the Board of General Directors, confirm that Separate Financial statements at as31/12/2025 prepared by us, give at true and fair view of the financial position, its operation result for the accounting period ended at the same day accordance with the Vietnamese Accounting System and comply with relevant statutory requirements.

In addition, the Board of Directors commits that the Company does not violate the obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC, dated November 16, 2020 of the Ministry of Finance guiding the disclosure of information on the Stock Market.

Hai Phong, 13/03/2026
On behalf of the Board of General Directors
General Director



Nguyen Thi Tu Anh



No.: 217 /BCKT-TC/AVA.NV7

INDEPENDENT AUDITOR'S REPORT

To: **Shareholders, the Board of Management and Board of General Director
Hai Duong Pharmaceutical Medical Materials Joint Stock Company**

We have audited the Separate Financial statements of Hai Duong Pharmaceutical Medical Materials Joint Stock Company, prepared on 13/03/2026, as set out on pages 06-35, including Statement of financial position as at 31/12/2025, Statement of comprehensive income, Statement of cash flows for fiscal year ended 31/12/2025 and Notes to financial statements.

Board of General Director' Responsibility

The Board of General Director is responsible for the preparation of Separate Financial statements that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to preparation and presentation of financial statements and for such internal control as management determines is necessary to enable the preparation of Separate Financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these Separate Financial statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with standards, ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Separate Financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Separate Financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the Separate Financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

74
TV
H
OÁ
M
LAI
TP.

Auditor's opinion

In our opinion, the Separate Financial statements give a true and fair view, in all material respects, of the financial position of Hai Duong Pharmaceutical Medical Materials Joint Stock Company as at 31/12/2025, and of the results of its operations and its cash flows for the year then ended in accordance with the Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to preparation and presentation of financial statements.



Tran Tri Dung
Vice General Director
Registration certificate
0895-2023-126-1
Ha Noi, 13/03/2026

Ngo Thị Thu Huyen
Auditor
Registration certificate
6103-2023-126-1

STATEMENT OF FINANCIAL POSITION
As at 31/12/2025

Unit: VND

ITEMS	Code	Note	31/12/2025	01/01/2025
A. CURRENT ASSETS	100		333,086,878,632	341,148,607,589
I. Cash and cash equivalents	110	V.1	44,408,946,125	31,419,168,182
1. Cash	111		44,408,946,125	31,419,168,182
II. Short-term accounts receivable	130		121,037,997,415	180,755,628,545
1. Short-term trade receivables	131	V.3	109,868,189,942	118,236,171,594
2. Short-term advances to suppliers	132	V.4	17,539,462,880	59,671,572,390
3. Other receivables	136	V.5	244,578,467	6,519,269,624
4. Provisions for short-term bad debts (*)	137	V.6	(6,614,233,874)	(3,671,385,063)
III. Inventories	140	V.7	143,634,151,611	127,909,053,084
1. Inventories	141		143,634,151,611	127,909,053,084
IV. Other current assets	150		24,005,783,481	1,064,757,778
1. Short-term prepaid expenses	151	V.8	784,391,367	624,164,224
2. VAT deductible	152		23,221,392,114	440,593,554
B. NON - CURRENT ASSETS	200		619,463,353,172	305,237,748,766
I. Fixed assets	220		471,482,526,434	277,938,572,145
1. Tangible fixed assets	221	V.9	453,231,176,078	259,687,221,789
- Cost	222		696,766,214,346	481,416,768,768
- Accumulated depreciation (*)	223		(243,535,038,268)	(221,729,546,979)
2. Intangible fixed assets	227	V.10	18,251,350,356	18,251,350,356
- Cost	228		25,557,287,846	25,557,287,846
- Accumulated depreciation (*)	229		(7,305,937,490)	(7,305,937,490)
II. Long-term assets in progress	240	V.11	142,391,317,925	24,432,507,459
1. Construction in progress	242		142,391,317,925	24,432,507,459
III. Long-term financial investments	250	V.2	1,835,000,000	-
1. Investment in subsidiaries	251		1,160,000,000	-
2. Investments held to maturity	255		675,000,000	-
IV. Other long-term assets	260		3,754,508,813	2,866,669,162
1. Long-term prepaid expenses	261	V.8	3,754,508,813	2,866,669,162
TOTAL ASSETS(270=100+200)			952,550,231,804	646,386,356,355

Form No. B 01 - DN

STATEMENT OF FINANCIAL POSITION

As at 31/12/2025

(Continuous)

Unit: VND

ITEMS	Code	Note	31/12/2025	01/01/2025
C. LIABILITIES	300		449,236,682,497	192,127,190,710
I. Current liabilities	310		212,182,405,640	186,108,895,749
1. Short-term Trade payables	311	V.12	74,933,027,107	63,913,046,095
2. Short-term Advances from customers	312	V.13	28,319,984,253	27,011,433,156
3. Tax payables and statutory obligations	313	V.14	10,009,726,250	7,152,037,955
4. Payables to employees	314		16,953,397,272	4,869,401,998
5. Short-term Accrued expenses	315	V.15	602,366,762	428,162,066
6. Short-term Unearned revenue	318	V.16	1,000,537,013	3,201,934,270
7. Short-term other payables	319	V.17	7,550,378,347	7,182,181,347
8. Short-term loans and debts	320	V.18	66,805,817,846	65,925,328,072
9. Bonus and welfare fund	322		6,007,170,790	6,425,370,790
II. Long-term liabilities	330		237,054,276,857	6,018,294,961
1. Long-term loans and debts	338	V.18	237,048,292,142	6,002,713,990
2. Science and Technology Development Fund	343		5,984,715	15,580,971
D. OWNER'S EQUITY	400		503,313,549,307	454,259,165,645
I. Equity	410	V.19	503,313,549,307	454,259,165,645
1. Contributed capital	411		359,959,290,000	279,473,170,000
- Ordinary shares with voting rights	411a		359,959,290,000	279,473,170,000
2. Investment and development fund	418		79,594,214,888	124,594,214,888
3. Undistributed earnings	421		63,760,044,419	50,191,780,757
- Undistributed profit after tax of previous period	421a		8,425,031,277	9,870,172,861
- Undistributed profit after tax of current period	421b		55,335,013,142	40,321,607,896
TOTAL RESOURCES(440=300+400)			952,550,231,804	646,386,356,355

Prepared by



Nguyen Thi Quynh Nga

Chief Accountant



Chu Van Long

Hai Phong, 13/03/2026

General Director



Nguyen Thi Tu Anh

STATEMENT OF COMPREHENSIVE INCOME
 Year 2025

Unit: VND

ITEMS	Code	Note	Year 2025	Year 2024
1. Revenue from sale of goods and rendering of services	01	VI.1	689,532,822,613	668,056,188,242
2. Deductible items	02	VI.2	5,819,302,260	3,054,479,448
3. Net revenue from sale of goods and rendering of services (10=01-02)	10		683,713,520,353	665,001,708,794
4. Cost of sales	11	VI.3	438,734,362,525	454,770,265,987
5. Gross profit from sale of goods and rendering of services (20=10-11)	20		244,979,157,828	210,231,442,807
6. Revenue from financial activities	21	VI.4	1,217,152,638	633,188,787
7. Finance costs	22	VI.5	5,681,886,282	6,255,488,148
<i>In which: Interest expenses</i>	23		3,177,483,945	3,218,208,599
8. Selling expenses	25	VI.6	79,028,832,449	74,149,536,551
9. General Administrative expenses	26	VI.6	93,156,777,114	81,814,791,647
10. Net profit from operating activities {30=20+(21-22)-(25+26)}	30		68,328,814,621	48,644,815,248
11. Other income	31	VI.7	1,983,041,896	2,152,468,731
12. Other expense	32	VI.8	546,295,012	8,775,306
13. Other profit (loss) (40=31-32)	40		1,436,746,884	2,143,693,425
14. Total profit before tax (50=30+40)	50		69,765,561,505	50,788,508,673
15. Current corporate income tax expenses	51	VI.10	14,062,371,303	10,179,727,977
16. Profit after tax (60=50-51-52)	60		55,703,190,202	40,608,780,696

Prepared by



Nguyen Thi Quynh Nga

Chief Accountant



Chu Van Long

Hai Phong, 13/03/2026

General Director



Nguyen Thi Tu Anh

STATEMENT OF CASH FLOWS
(Indirect method)
Year 2025

Unit: VND

Year 2025 Year 2024

ITEMS	Code	Note	Year 2025	Year 2024
I. Cash flows from operating activities				
1. Profit before tax	01		69,765,561,505	50,788,508,673*
2. Adjustment for				
- Depreciation and amortisation	02		27,896,857,741	27,261,433,809
- Provisions	03		2,942,848,811	3,671,385,063
- Gain/loss from unrealized foreign exchange difference	04		57,752,721	(50,857,754)
- Gain/loss from investment activities	05		(136,061,822)	(128,994,168)
- Interest expense	06		3,177,483,945	3,218,208,599
3. Profit from operating activities before changes in working capital	08		103,704,442,901	84,759,684,222
- Increase/Decrease in receivables	09		33,310,181,488	(48,775,880,044)
- Increase/Decrease in inventories	10		(15,725,098,527)	(23,555,535,012)
- Increase/Decrease in payables (excluding interest payables/ enterprise income tax payables)	11		(48,870,415,213)	40,089,010,412
- Increase/Decrease in prepaid expenses	12		(1,048,066,794)	4,803,425,508
- Interest expenses paid	14		(3,177,483,945)	(3,218,208,599)
- Corporate Income taxes paid	15		(11,535,675,825)	(5,592,091,588)
- Other expenses on operating activities	17		(918,596,800)	(525,180,334)
Net cash flows from operating activities	20		55,739,287,285	47,985,224,565
II. Cash flows from investing activities				
1. Purchase of fixed assets and other long-term assets	21		(267,499,306,224)	(25,268,805,054)
2. Proceeds from disposals of fixed assets and other long-term assets	22		99,149,092	181,809,091
3. Investments in other entities	25		(1,160,000,000)	-
4. Interest, dividends and profit received	27		36,912,730	29,742,305
Net cash flows from investing activities	30		(268,523,244,402)	(25,057,253,658)



Form No. B 03 - DN

STATEMENT OF CASH FLOWS
 (Indirect method)
 Year 2025
 (Continuous)

Unit: VND

ITEMS	Code	Note	Year 2025	Year 2024
III. Cash flows from financing activities				
1. Proceeds from short - term, long - term borrowings	33		373,496,645,091	152,833,226,632
2. Loan repayment	34		(141,570,577,165)	(163,680,154,573)
3. Dividends, profit paid to equity owners	36		(6,148,409,740)	(6,119,889,000)
Net cash flows from financing activities	40		225,777,658,186	(16,966,816,941)
Net decrease/increase in cash and cash equivalents	50		12,993,701,069	5,961,153,966
Cash and cash equivalents at beginning of the year	60		31,419,168,182	25,418,100,057
Impact of foreign exchange fluctuation	61		(3,923,126)	39,914,159
Cash and cash equivalents at end of the year	70		44,408,946,125	31,419,168,182

Prepared by



Nguyen Thi Quynh Nga

Chief Accountant



Chu Van Long

Hai Phong, 13/03/2026
 General Director



Nguyen Thi Tu Anh

101
 GT
 PHI
 VA
 YT
 (DI)
 (ON)
 (IA)
 (IA)
 (IA)

NOTES TO THE FINANCIAL STATEMENTS
Year 2025

I. Background

1. Forms of Ownership

Hai Duong Pharmaceutical Medical Materials Joint Stock Company.

The company operates under Business Registration Certificate No. 0800011018, registered for the first time on 04/04/2003, registered for the 23rd on 16/07/2025, Issued by the Department of Finance of Hai Phong City.

Head office: No. 102, Chi Lang Street, Thanh Dong Ward, Hai Phong City .

The Company's charter capital: 359,959,290,000 VND.

Total number of shares: 35,995,929 shares.

2. Business field

Business fields of the Company are Manufacturing, Trading, Trading Drugs, Pharmaceutical Chemicals and Medicinal Materials.

3. Business activities

According to the Business registration certificate, principal activities of the Company are:

- Production of drugs, pharmaceutical chemicals and medicinal materials. Details: Production of medicines, medicinal herbs, chemicals and essential oils;
- Manufacturing of medical, dental, orthopedic and rehabilitation equipment and instruments. Details: Manufacturing of medical supplies;
- Production of other foods that have not been classified anywhere. Details: Functional food production;
- Cosmetics production;
- Wholesale of pharmaceuticals and medical devices;
- Wholesale of other foods. Details: Wholesale of functional foods;
- Wholesale of perfumes, cosmetics and hygiene products;
- Wholesale of other chemicals (except for those used in agriculture). Details: Wholesale of chemicals used for the production of drugs, cosmetics, functional foods, for testing, for hospitals;
- Wholesale of medical machinery and equipment. Details: Wholesale of medical machinery, equipment, medical supplies;
- The rest of the specialized wholesalers have not been classified anywhere. Details: Wholesale of essential oils, medicinal herbs, eyeglasses;
- Retail of other goods that have not yet been classified in specialized stores.
Details: Retail of essence, medicinal materials, medical machinery and equipment, chemicals used for the production of drugs, cosmetics, functional foods, for testing, chemicals for hospitals;
- Retail of other foods in specialized stores. Details: Retail of functional foods;
- Planting medicinal plants; Other livestock. Breeding geckos and snakes (permitted by the State);
- Printing;
- Other professional, scientific and technological activities have not yet been classified. Details: Scientific and technical consulting services and technology transfer in the fields of medicine, pharmacy, cosmetics and food; quality inspection services of pharmaceuticals and functional foods;
- Transport of goods by road;
- Agent. Details: Agents for buying and selling medicines, cosmetic chemicals, functional foods, medical devices, medical equipment, eyeglasses, medicinal herbs, essential oils, chemicals;
- Trading in real estate, land use rights belonging to owners, users or leasers. Details: Houses for lease as offices, business locations, shops, warehouses, houses, yards;
- Hotel; Other personal service activities have not been classified anywhere. Details: Beauty care services;

- Brewing, distilling and preparing spirits; Wine production; Brewing beer and malt fermentation; Production of non-alcoholic beverages and mineral water;
- Construction of houses of all kinds; Construction of public-utility works; Construction of other civil engineering works;
- Demolition; Site preparation; Installation of electrical systems;
- Installation of water supply, drainage, heater and air conditioning systems; Installation of other construction systems; Completing construction works; Other specialized construction activities. Details: Construction of drug factory;
- Wholesale of beverages. Details: Wholesale of beer, wine, beverage;
- Advertise; Market research and public opinion polls; Early childhood education;
- Organizing trade introduction and promotion.

4. The Company's normal business period

The Company's normal business period is 12 months.

5. Operations of the company in the fiscal year affecting the financial statements

During the accounting period, the Company's operations did not have any significant characteristics that affected its own financial statements. The Company's operations took place normally in all periods of the year.

6. Business structure

The list of subsidiaries

Subsidiary name	Rate of interest	Rate of voting rights	Head office - Principle activities
Hai Duong Medical Supplies Pharmaceutical Co., Ltd.	100%	100%	1st Floor, No. 102 Chi Lang Street, Thanh Dong Ward, Hai Phong City - Retail of medicines, medical devices, cosmetics and hygiene items in specialized stores.

As of December 31, 2025, most of the Company's offices and production blocks are located at 102 Chi Lang Street, Thanh Dong Ward, Hai Phong City. In addition, the Company has 9 affiliated branches inside and outside the province:

- | | |
|---|---|
| <ol style="list-style-type: none"> 1. Cam Giang Branch 2. Hanoi Branch 3. Thanh Mien Branch 4. Ninh Giang Branch 5. Can Tho Branch | <ol style="list-style-type: none"> 6. Central Branch 7. Tu Ky Branch 8. Ho Chi Minh City Branch 9. Hai Duong 1 Branch |
|---|---|

Total number of employees

As at 31/12/2025, the Company has 771 employees (as at 01/01/2025, has 696 employees).

7. Statement of ability to compare information on Financial Statements

The financial statements of the Company are prepared to ensure comparability.

II. Accounting period and accounting monetary unit

1. Accounting period

Annual accounting period commences from 1st January and ends on 31st December.

2. Accounting monetary unit

Monetary unit used in accounting is Viet Nam Dong (National symbol is “đ”; International symbol is “VND”).

III. Accounting standards and Accounting system

1. Accounting System

The company applies Enterprise Accounting System issued under Circular No. 200/2014/TT-BTC dated 22 December, 2014 by Minister of Finance on guideline enterprise accounting and Circular No. 53/2016/TT-BTC dated 21 March, 2016 by Ministry of Finance amending and supplementing some articles of Circular No. 200/2014/TT-BTC.

2. Announcement on compliance with Vietnamese standards and accounting system

The company applies Vietnamese Accounting Standards and supplement documents issued by the State. Financial statements are prepared in accordance with regulations of each standard and supplement documents as well as with current accounting system.

IV. Accounting policies

1. Recognition of cash and cash equivalents

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of less than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of change in value.

When arising transactions in foreign currencies, foreign currencies shall be converted into Vietnam dong under the principle: Debit transactions are applied with actual exchange rates; Credit transactions are applied with weighted average exchange rates in book.

When preparing financial statements, in accordance with the law, balances in foreign currencies are re-evaluated at actual buying exchange rates of the commercial banks.

The actual exchange rate applied when re-evaluating the cash in hand, cash in bank in foreign currency is actual buying exchange rates of the commercial banks with which the company regularly transacts.

2. Financial investment

Investment in subsidiaries; joint-ventures, associates

Investments in subsidiaries over which the Company has control rights are stated at original cost. Distributions from accumulated net profits from subsidiaries arising subsequent to the date of acquisition are recognized in the Statement of comprehensive income. Other distributions received (in excess of such profits) are considered a recovery of investment and are deducted to the cost of the investment.

Investments in associates over which the Company has significant influence are stated at original cost. Distributions from accumulated net profits from associates arising subsequent to the date of acquisition are recognized in the Statement of comprehensive income. Other distributions received (in excess of such profits) are considered a recovery of investment and are deducted to the cost of the investment.

Investment in a joint venture entity is accounted by cost method and kept unadjusted thereafter for the post acquisition change in the venture's share of net assets of the joint venture entity. The Statement of comprehensive income reflects the venture's share of the net accumulated profits of the joint venture entity arising as from the contribution date.

Provision for devaluation of investment is made at the end of the year. The level of provision is determined based on the financial statements at the time of provisioning of the economic organization.

3. Receivables

Receivable are monitored in detail by maturity receivable, objects to be recovered and the type of original currency receivables, and other factors under the management of the Company.

The identification of necessary provision for doubtful debts is based on the items that are classified as short-term, long-term receivables on Balance Sheet. Provision for doubtful debts is made for each one based on the age of overdue debts or the estimated losses that may occur.

4. Inventory

Principles of recognizing inventories

The Company's inventories are assets bought to manufacture or sell in normal business period.

Inventories are stated at original cost. Where the net realizable value is lower than cost, inventories should be measured at the net realizable value. The costs of inventories comprise the purchase price, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

Method of calculating inventories

- Materials are imported in batches, the output price is calculated in name for each corresponding lot.
- Materials (including cars, boxes, boxes, etc.) that does not go in batches, the output price is calculated according to the monthly weighted average method.
- Processed finished products, finished products exported according to the nominal price method (any batch sold will be calculated according to the price of that lot)
- Finished products produced in the warehouse of the business room, goods according to the weighted average method after each import
- Unfinished production and business expenses are determined according to each unfinished production order at the end of the period, the value is calculated according to each batch put into production.

Method of accounting inventories

Inventory is recorded by perpetual.

11. 11. 11
11. 11. 11
11. 11. 11
11. 11. 11
11. 11. 11

11/11/11 10:11 AM

1131 - 6001211

16711. 0.0.0.1211

Method of setting up provision for devaluation of inventories

Provisions for devaluation of inventories made at the end of the year are the excess of original cost of inventory over their net realizable value.

5. Fixed assets and depreciation of fixed assets

Fixed assets

Fixed assets (tangible and intangible) are stated at the historical cost. During the using time, fixed assets (tangible and intangible) are recorded at cost, accumulated depreciation and net book value.

Depreciation is provided on a straight-line basis. The depreciation period is estimated as follows:

- Buildings	08 - 26 years
- Machine, equipment	05 - 10 years
- Transportation equipment	05 - 08 years
- Office equipment and furniture	03 - 05 years
- Land use rights	Indefinite
- Management software	03 years

The difference between net income from liquidation and sale and the residual value of fixed assets is recorded as income or expense in the report on income from business activities.

6. Principles for recording expenses for unfinished capital construction

Expenses for unfinished capital construction include expenses for construction and machinery that have not been completed or installed. Depreciation is not calculated for unfinished capital construction during construction and installation.

7. Prepaid expenses

Prepaid expenses only related to present fiscal year are recognised as short-term prepaid expenses and are recorded into operating costs.

Prepaid expenses incurred during the year but related to business operations of several years are recorded as long-term prepaid expenses and are amortized to the income statement in several years.

The calculation and allocation of long-term prepaid expenses to profit and loss account in the period should be based on nature of those expenses to select a reasonable method and allocated factors. Prepaid expenses are allocated partly into operating expenses on a straight-line basis.

The company's upfront expenses include the following expenses:

Tools and instruments: Valuable tools and instruments that have been put into use shall be allocated to expenses according to the straight-line method with an allocation period of not more than 36 months.

Fixed asset repair costs: One-time property repair costs of large value are allocated to straight-line costs over a 36-month period.

8. Payables

Payables are monitored in detail by maturity receivable, objects to be recovered and the type of original currency receivables, and other factors under the management of the Company.

When preparing financial statements, accountants base on remaining term of payables to classify them into short-term or long-term.

When there are evidences that a loss likely occurs, accountants need to immediately record a payable according to the precautionary principle.

Payables in foreign currencies need to be re-evaluated at the year end when preparing financial statements. Actual transacted exchange rate when re-evaluating payables in foreign currencies at the time of preparing financial statements is the published exchange rate of the commercial bank with which the Company often have transactions (selected by the Company when transacting with payable subjects).

9. Recognition of borrowings

Borrowings whose maturity time is over 12 months from the date of financial statements are presented as long-term borrowings and financial lease liabilities. Borrowings whose maturity time is within 12 months from the date of financial statements are presented as short-term borrowings and financial lease liabilities to prepare settlement plan.

When preparing financial statements, borrowings' balances in foreign currencies are re-evaluated in actual transacted exchange rate at the time of preparing financial statements.

Differences of exchange rate arising from payments and re-evaluation at the year end are recorded into financial incomes or expenses.

10. Recognition and capitalization of borrowing costs

Borrowing costs are recognized into operating costs during the period, except for which directly attributable to the acquisition, construction or production of a qualifying asset included (capitalized) in the cost of that asset, when gather sufficient conditions as regulated in SAV No. 16 "Borrowing costs".

Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset that takes more than 12 months to put into use under certified purposes or for sale should be included (capitalized) in the cost of that asset, including interest on borrowings, amortization of discounts or premiums relating to issuing bonds and ancillary costs incurred in connection with the arrangement of borrowings.

11. Accrued expenses

Payables for goods and services that are already received from suppliers or already supplied to buyers in the reported period but not actually paid due to shortage of bills or accounting files and documents are recognized as operating expenses of the reported period.

Recognizing accrued expenses into operating expenses in the period needs to be performed according to the matching principle between revenues and expenses incurred in the period.

Accrued expenses shall be balanced with actual incurred expenses. The difference between accrued and actual expenses shall be reversed.

12. Provision for payables

The amount recognised as a provision shall be the best estimate of the expenditure required to settle the present obligation at the end of year.

Only expenditures that relate to the original payables provision are set against it.

In case provision set for the previous period but not used up exceeds the one set for the current period, the difference is recorded as decrease in production and operation expenditures. The bigger difference of the payables provision on

Payables are recognized when the following conditions are satisfied:

- The Company has a current debt obligation (legal obligation or joint obligation) as a result of an event that
- The decline in economic benefits may occur leading to the requirement to pay debt obligations; and
- Provide a reliable estimate of the value of that debt obligation.

13. Principle of recognizing unearned revenue

Unearned revenue includes revenue received in advance such as: The amount of money that customers have paid in advance for one or more accounting periods of asset leasing; Interest received before lending or buying debt instruments; And other unearned revenues such as: The difference between the deferred or installment sale price as committed with the immediate payment price, the turnover corresponding to the value of goods or services or the amount to be deducted Discounted price for customers in traditional customer program.

Unearned revenue does not include:

- Advance payment from buyers whose enterprises have not provided products, goods and services;
- The revenue has not yet been collected from asset leasing activities, providing multi-period services.

Each accounting period, unrealized revenue is transferred into revenue in the period.

14. Principles for recognition of science and technology development funds

The science and technology development fund shall be accounted into enterprise management expenses to determine business results in the period. The appropriation and use of the scientific and technological development fund of enterprises must comply with the provisions of law.

15. Owner's equity

Principles of recognizing owner's equity, share premium, convertible bonds and other owner's equity

Owner's equity is stated at actually contributed capital of owners.

Premium reserve is recorded by the difference (over/under) between the selling price and the par value of treasury stocks when stocks are firstly or additionally issued or reissued. Direct expenses related to the additional issuance of shares or reissuing treasury stock is recorded to reduce the surplus capital stock.

Recognition Undistributed profit

Profit after tax retained is the profit of business operations after deduction (-) regulated items due to applying a change in accounting retrospectively or to make a retrospective restatement to correct materiality in previous years. The profit is available for appropriation to investors after approval by Board of Management and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnamese regulatory requirements.

16. Revenue

Sale of goods

Revenue from sale of goods should be recognized when all the following conditions have been satisfied:

- The entity has transferred to the buyer the significant risks and rewards of ownership of the goods;
- The entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- The amount of revenue can be measured reliably;
- It is probable that The economic benefits associated with the transaction will flow to the entity;
- The cost incurred or to be incurred in respect of the transaction can be measured reliable.

Rendering of services

When the outcome of a transaction involving the rendering of services can be estimated reliable, revenue associate with the transaction shall be recognised by reference to the stage of completion of the transaction at the end of reporting period. The outcome of a transaction can be estimated reliable when all the following conditions are satisfied:

- The amount of the revenue can be measured reliably;
 - It is probable that the economic benefits associated with the transaction will flow to the entity;
 - The stage of the completion of the transaction at the end of the reporting period can be measured reliably; and
 - The costs incurred for the transaction and the costs to complete the transaction can be measured reliable.
- The stage of the completion of the transaction may be determined by surveys of work completed methods.

Financial income

Revenue arising from the used by the others of entity assets yielding interest, royalties and dividends shall be recognised when:

- It is probable that the economic benefits associated with the transaction will flow to the entity;
- The amount of the revenue can be measured reliably.

Dividends shall be recognised when the shareholder's right to receive payment is established.

Common Stocks and Dividends paid by Stocks: No record earnings when the right to receive bonus shares or dividend shares is established, the number of bonus shares and dividend shares received disclosure in Financial Statements.

Other revenues

Recognition of other revenues beside the entity's business activities includes:

- Revenue from liquidation of fixed assets;
- Revenue from fines paid by customers for breaching contracts;
- Revenue from the third party's compensation for a loss of property (e.g. insurance compensation, compensation for relocating business office and other similar revenues);
- Collection of bad debts which have been written off;
- Revenue from payables which is not identified;
- Other revenues than those listed above.

17. Deductibles from revenue

Deductibles adjusted to revenues from sale of goods and rendering of services arising in the period include: Sale discounts, sale rebates and sale returns.

Trade discounts, discounted sales, sales generated bounces same period consumption of products, goods and services are adjusted periodically generated revenue;

In case that products, goods and services have already been consumed since the previous period, but until the subsequent period, sale discounts, sale rebates or sale returns incur, then the Company recognizes deductibles from revenue according to the following requirements:

- If products, goods and services have already been consumed since the previous period and need to be discounted, rebated, returned in the subsequent period but before the time of issuing financial statements, accountants recognize it as an event that needs to be adjusted arising after the date of Balance Sheet and deduct revenues of the period's financial statements (the previous period).
- In case that products, goods and services need to be discounted, rebated, returned after the time of issuing financial statements, the entity needs to deduct revenues of the arising period (the subsequent period).

18. Cost of goods sold

Reflecting the cost value of products, goods and services sold in the period.

The provision for devaluation of inventories is included in the cost of goods sold on the basis of the number of inventories and the difference between the net realizable value is less than the cost of inventories.

When selling products and goods with equipment and spare parts, the value of equipment and spare parts is recorded into cost of goods sold.

As for the value of inventory shrinkage and loss, accountants immediately count towards cost of goods sold (after deducting the compensation, if any).

As for the cost of direct materials consumed in excess of normal level, labour cost, fixed general operation unallocated to the value of products stocked, accountants immediately count them towards in cost of goods sold (after deducting the compensation, if any) even if the products and goods have not been determined to be consumed.

Import duties, special consumption taxes and environmental protection taxes have been included in the value of purchased goods, and when the goods are sold, those taxes are refunded, the decrease of the cost of goods sold is recorded.

As for costs of goods sold unrecognized as corporate income taxable expenses under the regulations of Tax law but with full of invoices and documents and accounted reasonably under Accounting system, the Company does not reduce accounting expenses but adjusts in the corporate income tax settlement to increase corporate income tax payable.

19. Financial expenses

Reflecting financial expenses including expenses or losses related to financial investment activities, expenses of lending and borrowing equity, expenses of contributing in joint ventures, associates, losses of transferring short-term securities, expenses of selling securities transactions; Provision for devaluation of trading securities, provision for loss of investments in other entities, losses of selling foreign currencies, losses of exchange rate...

As for financial expenses unrecognized as corporate income taxable expenses under the regulations of Tax law but with full of invoices and documents and accounted reasonably under Accounting system, the Company does not reduce accounting expenses but adjusts in the corporate income tax settlement to increase corporate income tax payable.

20. Selling expenses and administrative expenses

Expenses recognized as selling expenses include: Expenses actually arising in process of selling products, goods and rendering services including expenses for offering, introducing, advertising products, sale commissions, expenses for products' warranty, storage, packing, transporting, ...

Expenses recognized as administrative expenses include: Expenses for administrative labour (salaries, wages, allowances,...); social insurance, health insurance, union fund, unemployment insurance of administrative staffs; expenses of office commodities, working tools, depreciation of fixed assets used for administration; land rent, excise; provision for doubtful receivables; outside purchasing costs (electricity, water, telephone, fax, asset insurance, fire insurance...); other costs in cash (guest receptions, customer conferences...).

As for selling expenses and administrative expenses unrecognized as corporate income taxable expenses under the regulations of Tax law but with full of invoices and documents and accounted reasonably under Accounting system, the Company does not reduce accounting expenses but adjusts in the corporate income tax settlement to increase corporate income tax payable.

21. Principles and methods of recognizing current corporate income tax and differed corporate income tax charge

Current corporate income tax expense is the amount of corporate income tax payable counted on taxable income in the period and prevailing tax rate.

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted by the balance sheet date.

22. Other accounting principles and methods

22.1. Basis for consolidation of financial statements

The financial report is presented according to the historical cost convention.

22.2. Related parties

Enterprises and individuals that directly or indirectly through one or more intermediaries, have control on or are under control of the Company, or are under common control with the Company, including parent companies, subsidiaries and associates are related parties. Associates and individuals that directly or indirectly hold voting right of the Company and have a significant impact on the Company, key management personnel including Board of Directors and employees of the Company, closed family members of these individuals or these associates or companies associated with these individuals are also considered as related parties.

In considering each relationship of related parties, it is necessary to pay attention to the nature of the relationship, not only its legal form.

V. Descriptive information in addition to items presented in the Balance sheet

		Unit: VND	
		31/12/2025	01/01/2025
1. Cash			
Cash on hand		3,690,276,243	2,584,400,686
Demand deposits		40,718,669,882	28,834,767,496
		44,408,946,125	31,419,168,182

2. Financial investments

Investments held to maturity

	31/12/2025		01/01/2025	
	Original cost	Book value	Giá gốc	Book value
Long-term				
Term deposits (*)	675,000,000	-	-	-
	675,000,000	-	-	-

(*) The deposit with a term of 638 days is deposited at BIDV Bank - Hai Duong Branch with an interest rate of 4.7%/year.

Equity investments in other entities

	31/12/2025		01/01/2025	
	Original cost	Provisions	Original cost	Provisions
Investments in subsidiaries				
Hai Duong Pharmaceutical Medical Supplies Co., Ltd. (i)	1,160,000,000	-	-	-
	1,160,000,000	-	-	-

Information about the Company's subsidiaries as of 31/12/2025 is as follows:

(i) The investment has an interest ratio and a voting right ratio of 100%.

The Company has not determined the fair value of these financial investments to be explained in its separate financial statements because these investments do not have a market price and the Vietnam Accounting Standards, Vietnam Corporate Accounting Regime and legal regulations related to the preparation and presentation of financial statements. There are no detailed instructions on how to calculate fair value. The fair value of these financial investments may differ from the book value.

3. Receivables

	31/12/2025	01/01/2025
Short-term		
KARUNA PHARMA CO,LTD	4,429,531,934	6,520,562,745
Nam Sach Medical Center	1,936,770,640	7,382,561,150
Binh Giang Medical Center	3,050,841,914	2,482,472,650
Tu Ky District Medical Center	2,393,483,260	4,355,255,977
Thanh Ha Medical Center	1,013,609,868	3,272,031,580
Thanh Duoc Joint Stock Company	2,497,096,011	935,793,512
Nam Viet Trading and Pharmaceutical Joint Stock Company	2,431,067,808	1,381,227,118
Ninh Giang Medical Center	1,433,698,037	1,950,833,985
Golden Health USA Co., Ltd.	1,476,408,319	2,259,924,512
7679 Investment and Trading Joint Stock Company	1,842,230,166	1,322,903,698
Others	87,363,451,985	86,372,604,667
	109,868,189,942	118,236,171,594

4. Advances for suppliers

	31/12/2025	01/01/2025
Short-term		
IMA Pacific Company Limited	3,232,180,224	21,242,959,500
ALEXANDERWERK GMBH	-	4,082,243,787
GEA Process Engineering (India) Pvt Ltd (Unit II, 100% EOU)	-	5,925,729,471
Truking Watertown Pharmaceutical Equipment Co., Ltd	406,922,100	4,155,102,900
Alphaco Hanoi Construction Joint Stock Compan	-	5,855,966,623
Bach Khoa Thermoelectric Refrigeration Co., Ltd.	-	10,398,888,889
Tofflon Science and Technology Group Co.,Ltd	5,475,835,500	-
Sao Nam Chemical Trading Technical Services Co., Ltd	3,585,920,000	-
Others	4,838,605,056	8,010,681,220
	17,539,462,880	59,671,572,390

5. Other receivables	31/12/2025		01/01/2025	
	Value	Provision	Value	Provision
Short-term				
Other parties				
Advances	155,711,472	-	499,614,849	-
Deposit, other short-term margin	51,821,055	-	68,450,775	-
Others	37,045,940	-	51,204,000	-
Related parties				
Mr. Nguyen Trung Viet	-	-	5,900,000,000	-
	244,578,467	-	6,519,269,624	-

6. Bad debt	31/12/2025		01/01/2025	
	Original value	Recoverable amount	Original value	Recoverable amount
The total value of overdue and unrecoverable receivables				
Trang Minh Pharmaceutical Joint Stock Company	49,439,590	-	49,439,590	-
Linh Son - Nghe An Pharmaceutical Joint Stock Company	160,548,293	-	160,548,293	-
Thai Tien Pharmaceutical Joint Stock Company	339,120,218	-	339,120,218	-
Tri Duc Pharmaceutical - Medical Equipment Co., Ltd.	191,784,964	-	191,784,964	-
Nhat Quang Pharmaceutical Trading Co., Ltd. (Viet Tri)	418,102,630	-	418,102,630	-
OPM Pharmaceutical Company Limited	1,147,705,903	-	1,147,705,903	-
Hanoi Pharmaceutical and Commercial Services Joint Stock Company	184,939,112	-	184,939,112	-
Tam Viet Pharmaceutical and Medical Equipment Joint Stock Company	186,592,364	-	186,592,364	-
T.H.I Joint Stock Company	74,588,048	-	74,588,048	-
Truong Xuan Pharmaceutical Joint Stock Company	78,056,427	-	78,056,427	-
Arenphar Investment & Trading Joint Stock Company	16,496,548	-	16,496,548	-

Biofocus Biotechnology Pharmaceutical Joint Stock Company	43,688,992	-	43,688,992	-
HAPHARMA Joint Stock Company	280,090,264	-	280,090,264	-
Nam Lang Oriental Medicine and Pharmacy Joint Stock Company	121,888,331	-	121,888,331	-
Tran Manh Tinh	378,343,379	-	378,343,379	-
Golden Health USA Co., Ltd. (KH)	1,387,457,495	-	-	-
TBK Medical Joint Stock Company	39,457,915	-	-	-
Son Thuy Pharmaceutical Co., Ltd.	19,883,845	-	-	-
Ky Thien Pharmaceutical Joint Stock Company	13,212,761	-	-	-
Tue Phuc Investment & Trading Co., Ltd.	23,394,500	-	-	-
Nguyen Thi Thanh (Tue Phuc)	79,365,000	-	-	-
Pharmacy No. 72	44,404,930	-	-	-
Super France Pharmaceutical Co., Ltd	132,766,371	-	-	-
Thien Viet Pharmaceutical Trading Co., Ltd.	20,000,000	-	-	-
Alpharco International Joint Stock Company	232,017,586	-	-	-
Thien Phu Trading Development and Investment Joint Stock Company	239,001,424	-	-	-
Hai Phong Transport Hospital	132,718,928	-	-	-
Branch of Hanoi Pharmaceutical and Trading Services Joint Stock Company in Son La	111,682,378	33,504,713	-	-
Other Customers	500,990,391	-	-	-
	6,647,738,587	33,504,713	3,671,385,063	-



7. Inventories	31/12/2025		01/01/2025	
	Original value	Provision	Original value	Provision
Raw material	58,095,609,924	-	54,200,285,889	-
Tools, supplies	473,710,871	-	-	-
Work in process	12,156,670,958	-	15,202,316,672	-
Finished goods	66,590,004,113	-	52,911,355,963	-
Merchandise	6,318,155,745	-	5,595,094,560	-
	143,634,151,611	-	127,909,053,084	-

8. Prepaid expenses	31/12/2025	01/01/2025
8.1. Short-term Instruments and tools	784,391,367	624,164,224
	784,391,367	624,164,224
8.2. Long-term Instruments and tools	3,754,508,813	2,866,669,162
	3,754,508,813	2,866,669,162

9. Tangible fixed assets	Appendix No. 01			
10. Intangible fixed assets				
Items	Land use rights	Publishing titles	Copyrights and patents	Total
Original cost				
As at 01/01/2025	20,651,287,846	-	4,906,000,000	25,557,287,846
As at 31/12/2025	20,651,287,846	-	4,906,000,000	25,557,287,846
Accumulated depreciation				
As at 01/01/2025	2,399,937,490	-	4,906,000,000	7,305,937,490
As at 31/12/2025	2,399,937,490	-	4,906,000,000	7,305,937,490
Net carrying amount				
As at 01/01/2025	18,251,350,356	-	-	18,251,350,356
As at 31/12/2025	18,251,350,356	-	-	18,251,350,356
Cost of fully depreciated intangible fixed assets but still in use:				7,305,937,490

11. Long-term assets in progress

11.1 Construction in progress

	31/12/2025	01/01/2025
Purchase		
Procurement costs of fixed assets for Cam Thuong Phase 2 factory	14,724,084,575	-
Construction in progress		
EU GMP standard consulting cost of Cam Thuong factory project phase 2	7,855,735,015	5,921,925,093
Cost of consultancy + design and construction of Cepharlosprorin GMPEU Line - Phase 2 Project	101,807,305,355	12,855,006,168
Medium-term interest expense of the project	8,619,146,666	-
Value of land use rights L09-54, L09-53 in Can Tho	5,830,490,932	5,655,576,198
Fire Protection System Manufacturer 4c	2,915,476,350	-
EU GMP Verification Document Cost of D/C Powdered Cephalosprin	639,079,032	-
	142,391,317,925	24,432,507,459

12. Payables to suppliers

	Value and Realizable value	
	31/12/2025	01/01/2025
Short-term		
GSTC., CORP	3,014,460,000	-
Hanoi International Pharmaceutical Chemical Joint Stock Company	750,390,000	3,087,099,550
Van Xuan Pharmaceutical Trading Co., Ltd.	3,011,560,416	3,011,560,416
INC. PHARMA .,JSC	1,212,300	2,634,839,674
CGP Vietnam Joint Stock Company	3,652,635,000	-
Duc Thanh Packaging and Trading Manufacturing Co., Ltd	1,959,930,482	1,715,471,805
Dong Au Production And Trading Company Limited	3,246,340,931	2,685,110,449
Công ty TNHH cơ nhiệt điện lạnh Bách Khoa	5,398,660,354	-
Thuan An Phat Pharmaceutical Joint Stock Company	11,551,948	3,882,712,100
FRESENIUS KABI VIETNAM Joint Stock Company	1,757,368,320	3,357,870,838
Others	52,128,917,356	43,538,381,263
	74,933,027,107	63,913,046,095

13. Advances from customers

	31/12/2025	01/01/2025
Short-term		
Ha Minh Trading and Technology Co., Ltd.	2,214,177,730	3,682,738,650
SOLPHARMA Co., Ltd.	2,920,150,100	886,690,000
Summer Jordan for Storage & General Trading	-	1,510,800,000
2B Trading and Service Co., Ltd.	1,218,322,263	495,521,250
VP-PHARM Pharmaceutical Joint Stock Company	917,003,829	478,725,045
Sanoji World Joint Stock Company (Bayer World).	413,812,000	360,003,234
World Roche Joint Stock Company (Bayer World).	1,570,204,320	492,650,000
World Roche Joint Stock Company (Bayer World)	-	618,405,600
Hai Duong Psychiatric Hospital	-	199,456,740
Hanoi Pharmaceutical Import and Export - Medical Equipment Joint Stock	550,000,000	-
Nguyen Van Thanh (Quang Binh)	500,000,000	500,000,000
Hanoi SKV Joint Stock Company	489,274,485	460,792,500
Thien Y Pharma Co., Ltd. (Phuc An pharma)	715,470,000	-
Others	16,811,569,526	17,325,650,137
	28,319,984,253	27,011,433,156

14. Taxes and payables to the state budget

Payables

	<u>31/12/2025</u>	<u>Payables</u>	<u>Already paid</u>	<u>01/01/2025</u>
Value-added tax	-	61,514,854,934	61,514,854,934	-
Export, import duties	-	24,879,183	24,879,183	-
Business income tax	9,032,800,003	14,395,818,051	11,665,247,125	6,302,229,077
Personal income tax	976,926,247	3,143,471,331	3,016,353,962	849,808,878
Property tax and land rental	-	1,307,178,869	1,307,178,869	-
Other taxes	-	253,881,092	253,881,092	-
	<u>10,009,726,250</u>	<u>80,640,083,460</u>	<u>77,782,395,165</u>	<u>7,152,037,955</u>

(*) Business income tax payable includes:

Expenses for administrative penalties according to the tax inspection record	333,446,748
Applicable tax costs	14,062,371,303
Corporate income tax actually paid:	11,535,675,825

The Company's tax settlements are subject to examination by the tax authorities. Because the application of tax laws and regulations on many types of transactions is susceptible to varying interpretations, amounts reported in the financial statements could be changed at a later date upon final determination by the tax authorities.

15. Accrued expenses

	<u>31/12/2025</u>	<u>01/01/2025</u>
Short-term		
Remuneration of the Board of Directors, Control Board, secretary	530,784,858	356,580,162
Other expenses	11,581,904	71,581,904
Others	60,000,000	-
	<u>602,366,762</u>	<u>428,162,066</u>

16. Unearned revenue

	<u>31/12/2025</u>	<u>01/01/2025</u>
16.1. Short-term		
Revenue received in advance for product registration services	691,964,286	2,876,270,633
Rentals, premises	308,572,727	325,663,637
	<u>1,000,537,013</u>	<u>3,201,934,270</u>

17. Other payables

	<u>31/12/2025</u>	<u>01/01/2025</u>
17.1. Short-term		
Other parties		
Other payables (Processing customers who place domestic and foreign product registration fees are in the process of implementation and have not yet been finalized):	7,550,378,347	7,182,181,347
<i>IPP Pharmaceutical Trading Co., Ltd.</i>	2,231,250,000	4,621,673,047
<i>Green Vietnam Pharmaceutical Trading Co., Ltd.</i>	495,000,000	495,000,000
<i>Alpha France Pharmaceutical Trading Joint Stock Company</i>	200,000,000	200,000,000
<i>Santa Vietnam Pharmaceutical Joint Stock Company</i>	50,000,000	270,000,000
<i>Value-added tax</i>	4,574,128,347	1,595,508,300
	<u>7,550,378,347</u>	<u>7,182,181,347</u>

18. Loans and debts

18.1. Short-term loans and debts

	Value and able to pay			
	31/12/2025	Increase	Decrease	01/01/2025
Banks	66,524,817,846	132,152,188,912	131,271,699,138	65,644,328,072
Hai Duong Joint Stock Commercial Bank for Industry and Trade (i)	20,873,218,829	46,971,675,819	59,272,255,286	33,173,798,296
Vietnam International Commercial Joint Stock Bank - Hai Duong Branch	-	19,611,902,457	35,620,348,069	16,008,445,612
Hai Duong Joint Stock Commercial Bank for Investment and Development - Transaction Office Tran Hung Dao (ii)	45,651,599,017	65,568,610,636	36,379,095,783	16,462,084,164
Vietnam Prosperity Joint Stock Commercial Bank (VP bank) - Hai Duong Branch	-	10,029,193,827	10,029,193,827	-
Organizations, individuals	281,000,000	80,000,000	80,000,000	281,000,000
Employee loans	281,000,000	80,000,000	80,000,000	281,000,000
	66,805,817,846	142,261,382,739	141,380,892,965	65,925,328,072

18.2. Long-term loans and debts

	Value and able to pay			
	31/12/2025	Increase	Decrease	01/01/2025
Loans from banks	235,084,365,709	-	-	3,849,103,357
Hai Duong Joint Stock Commercial Bank for Investment and Development - Transaction Office Tran Hung Dao (iii)	235,084,365,709	231,235,262,352	-	3,849,103,357
Organizations, individuals	1,963,926,433	-	189,684,200	2,153,610,633
Employee loans (iv)	1,963,926,433	-	189,684,200	2,153,610,633
	237,048,292,142	231,235,262,352	189,684,200	6,002,713,990

Detail information on Long-term loans as at 31/12/2025

- (i) Loan limit contract No. 01/CNHD1/2025-HDCVHM/NHCT340/DUOCVTTYT dated 20/03/2025; Credit limit: 50,000,000,000 VND. Purpose: to supplement working capital for the production and trading of pharmaceuticals, medical supplies and equipment. Duration of limit maintenance: 12 months from the date of signing the contract. Contract No. 01/CNHD1/2025-HDCVHM/NHCT340/DUOCVTTYT includes debts adjusted by the line loan contract No. 02.10/2023-HDCVHM/NHCT340-DUOCVTTYT dated October 18, 2023 and the amending and supplementing document No. 02.10/2023-HDCVHM/NHCT340-DUOCVTTYT/SDBS01 signed on October 16, 2024. Interest rate: the loan interest rate is specified on the Debt Receipt for each disbursement. Collateral: Mortgage contract of land-attached assets No. 16.09/CNHD9/2016/HDTTC/DUOC-VTTYT dated 19/09/2016 and documents amending and supplementing the Mortgage Contract attached.
- (ii) Credit contract No. 01/2025/222776/HDTD dated 01/10/2025; Credit limit: VND 100,000,000,000 including Vietnamese dong and foreign currency converted (including all short-term loan balances, guarantee balances, L/C issuance under the Credit Limit Agreement No. 02/2024/222776/HDTD dated 04/09/2025 to . Purpose: supplementing working capital, guarantee, issuing L/C. Term: from 01/10/2025 to 30/09/2026 (term: 12 months from the date of signing the contract). Interest rate: the loan interest rate is specified on the Debt Receipt for each disbursement. Collateral:
- Mortgage contract No. 01/2019/222776/HDBD dated 16/10/2019 signed between Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company and Joint Stock Commercial Bank for Investment and Development of Vietnam - Hai Duong Branch.
 - Mortgage contract for assets attached to land to be formed in the future No. 01/2020/222776/BBDG dated 03/06/2020 signed between Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company and Joint Stock Commercial Bank for Investment and Development of Vietnam - Hai Duong Branch.
 - Mortgage contract for future assets No. 02/2024/222776/HDBD dated 04/09/2024 signed between Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company and Joint Stock Commercial Bank for Investment and Development of Vietnam - Hai Duong Branch.
 - Mortgage contract of land-attached assets No. 01/2024/222776/HDBD dated 09/09/2024 signed between Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company and Joint Stock Commercial Bank for Investment and Development of Vietnam - Hai Duong Branch.
 - Deposit pledge contract No. 01/2025/222776/HDCC dated 29/09/2025 signed between Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company and Joint Stock Commercial Bank for Investment and Development of Vietnam - Hai Duong Branch.
- (iii) Credit contract No. 01/2024/222776 dated 04/09/2024; Credit limit: 236,500,000,000 VND. Purpose: loans/guarantees/L/C will be used to finance reasonable investment costs for the implementation of the GMP-EU standard injections, tablets and herbal medicine factory Phase 2, project: GMP-EU antibiotic powder and beta lactam drug production line. Duration of issuance of contractual commitments: 120 months from the date of the first disbursement/issuance of the first letter of credit/guarantee in which the original grace period is 24 months from the date of signing this credit contract. Interest rate: the loan interest rate is 6.5%/year fixed for the first 02 years, then applied according to the floating interest rate of the credit provider. Collateral: Mortgage contract No. 01/2019/22277/HDBD dated 16/10/2019 and mortgage contract for assets attached to land to be formed in the future No. 01/2020/22277/BBDG dated 03/06/2020 signed between VTYT Hai Duong Pharmaceutical Joint Stock Company and Vietnam Bank for Investment and Development - Hai Duong Branch.
- (iv) Including loan contracts for officials and employees with a term of more than 12 months, interest rate of 6%/year, no collateral.

19. Owner's equity

19.1. Increase and decrease in owner's equity
Appendix No. 02

	Year 2025	Year 2024
Earnings distribution		
Total profit of the previous period carried forward	50,191,780,757	41,544,595,561
Profit after tax in the period	55,703,190,202	40,608,780,696
Increase, decrease () other	(500,396,800)	(364,836,500)
Earnings distribution of the previous year, in which:	41,634,529,740	31,596,759,000
Increase in Equity	35,486,120,000	25,476,870,000
Dividend Payment	6,148,409,740	6,119,889,000
Undistributed profit after tax at the end of the period	63,760,044,419	50,191,780,757

19.3. The details of the owner's equity

	31/12/2025		01/01/2025	
	Rate (%)	Value	Rate (%)	Value
Contributed capital of shareholders	100.00	359,959,290,000	100.00	279,473,170,000
	100.00	359,959,290,000	100.00	279,473,170,000

19.4. Capital transactions with owners and distribution of dividends and profits

	Year 2025	Year 2024
Owner's Equity		
Opening balance	279,473,170,000	203,996,300,000
Increase in the period	80,486,120,000	75,476,870,000
Decrease in the period	-	-
Closing balance	359,959,290,000	279,473,170,000

Dividends, profits shared

Dividends distributed on last year profit

Year 2025	Year 2024
6,148,409,740	

19.5. Stock

Quantity of registered issuing stocks
Quantity of Authorized issuing stocks
Common stocks
Quantity of Outstanding Stocks
Common stocks
Par value of Stocks

31/12/2025	01/01/2025
35,995,929	27,947,317
35,995,929	27,947,317
35,995,929	27,947,317
10,000	10,000

19.6. Funds in Company

Development and Investment Fund

79,594,214,888	124,594,214,888
----------------	-----------------

20. Items outside the Balance Sheet

Foreign currency

USD
EUR

31/12/2025	01/01/2025
52,165.00	154,688.59
90,702.00	4,001.43

VI. Descriptive information in addition to the items presented in the Income statement

Unit: VND

		Year 2025	Year 2024
1.	Total revenues from sale of goods and rendering of services		
	Revenue from sale of goods	671,889,662,787	657,352,412,747
	Revenue from sales of goods and finished products	17,643,159,826	10,703,775,495
	Revenue from service provision		
		689,532,822,613	668,056,188,242
2.	Deductible items		
	Trade Discounts	4,081,450,910	1,195,909,160
	Devaluation of sale	64,458,698	272,692,714
	Sales returns	1,673,392,652	1,585,877,574
		5,819,302,260	3,054,479,448
3.	Cost of good sold		
	Cost of good sold	438,734,362,525	454,770,265,987
		438,734,362,525	454,770,265,987
4.	Financial incomes		
	Interests of bank deposits and loans	36,912,730	29,742,305
	Interest on exchange rate difference in the period	1,180,239,908	603,446,482
		1,217,152,638	633,188,787
5.	Financial expenses		
	Interests of borrowing	3,177,483,945	3,218,208,599
	Interest on exchange rate difference in the period	1,190,434,227	1,191,588,287
	Loss on exchange rate difference in the period	1,313,968,110	1,845,691,262
		5,681,886,282	6,255,488,148
6.	Selling and general administrative expenses		
	Selling expenses	57,490,105,556	52,045,545,103
	Labour expenses	2,353,947,295	2,691,974,910
	Depreciation expenses	7,792,921,309	6,574,276,539
	Expenses from external services	11,391,858,289	12,837,739,999
	Other expenses by cash		
		79,028,832,449	74,149,536,551

174.
 TY
 H
 OÁN
 NH
 AM
 P.W

General administrative expenses	42,943,434,725	37,682,808,567
Management staff	8,322,206,419	5,678,635,404
Raw materials	1,753,060,184	4,374,140,857
Tools, utensils	3,981,804,619	3,937,453,862
Depreciation expenses	1,304,332,175	1,194,703,208
Tax, Charge, Fee	5,850,259,285	7,639,626,005
Provision expenses	6,459,975,058	5,907,544,016
Expenses from external services	22,541,704,649	15,399,879,728
Other expenses by cash		
	93,156,777,114	81,814,791,647
7. Other income	Year 2025	Year 2024
Income from liquidating, disposing fixed assets	99,149,092	99,251,863
Other income	1,883,892,804	2,053,216,868
	1,983,041,896	2,152,468,731
8. Other expense	Year 2025	Year 2024
Tax penalties, administrative violations penalties	546,295,012	8,775,306
	546,295,012	8,775,306
9. Business and productions cost by items	Year 2025	Year 2024
Cost of materials	294,917,505,042	276,627,947,622
Labour cost	136,111,107,037	123,221,929,065
Depreciation	27,896,857,741	27,261,433,809
Outside purchase services cost	43,101,588,614	42,191,441,087
Other expenses	51,163,421,001	47,124,725,201
	553,190,479,435	516,427,476,784

10. Income Tax	Year 2025	Year 2024
Corporate income tax from main business field	69,765,561,505	50,788,508,673
Total profit before tax	546,295,012	187,718,967
Increase	-	187,718,967
Invalid payment	-	178,943,661
Other expenses that are not deductible (cancellation of bad debts)	546,295,012	8,775,306
Penalties for administrative violations, tax penalties	-	(77,587,754)
Decrease ()	-	(77,587,754)
Interest on exchange rate differences, revaluation of money and receivables	-	(77,587,754)
Taxable income	70,311,856,517	50,898,639,886
Current corporate income tax expense	14,062,371,303	10,179,727,977
Adjustment of previous year corporate income tax expense to this year corporate income tax expense	-	-
Current corporate income tax expense	14,062,371,303	10,179,727,977

VII. Other information

Unit: VND

1. Events after the reporting period

There have been no significant events occurring after the reporting period, which would require adjustments or disclosures to be made in the financial statements.

2. Information on related parties

2.1. List of related parties

<u>Related parties</u>	<u>Relationship</u>
Members of the Board of Management, Board of Directors	Key Managing Member
Family members of the Board of Management, Board of Directors	Individuals related to key management members

2.2. During operation, there are a number of transactions between the company and related parties as follows:

<u>Contents/ Related parties</u>	<u>Year 2025</u>	<u>Year 2024</u>
Dividend Payment		
Mr. Nguyen Trung Viet (Chairman of the Board of Management)	2,000,000,000	2,499,591,600
Ms. Nguyen Mai Lan (Wife of Mr. Nguyen Trung Viet)	400,000,000	1,002,906,000
Reimburse		
Mr. Nguyen Trung Viet (Chairman of the Board of Management)	5,900,000,000	

2.3. Outstanding balances with related parties up to the reporting date are as follows

Balances with related parties at the balance sheet date are presented in Note V.

2.4. Income of the Board of Directors, the Board of Directors and the Supervisory Board

Sl. No.	Name	Title	Year 2025	Year 2024
1	Nguyen Trung Viet	Chairman of the Board of Management	631,624,049	470,856,500
2	Tran Phuc Duong	Member of the Board of Management	500,396,800	364,836,500
3	Nguyen Thi Tu Anh	Member of the Board of Management, General Director	924,081,318	797,466,720
4	Dang Van Viet	Quality Manager	435,254,120	447,057,087
5	Pham Van Nam	Sales Director	877,222,670	584,380,363
6	Pham Thi Thuy	Head of the Supervisory Board	378,331,318	365,271,610
7	Tran Kim Cuong	Members of the Supervisory Board	350,039,538	303,325,764
8	Nguyen Thi Huong Lan	Members of the Supervisory Board	479,628,775	390,399,931
Total			2,031,589,376	1,405,256,148

3. Presentation of assets, revenue, business results by division

The Company does not prepare segment statements because of not satisfying 1 in 3 conditions about preparing segment statements upon business field or geographical area required in Circular No. 20/2006/TT-BTC dated on 20 March 2006 of the Ministry of Finance guiding the implementation of six (06) accounting standards issued under Decision No. 12/2005/QĐ-BTC dated 15 February 2005 of the Minister of Finance.

4. Comparative information

The comparative data is the data on the 2024 Financial Statement of Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company which has been audited by Vietnam Auditing and Valuation Co., Ltd.

5. Continuous Operation Information

There are no events that cause serious doubts about its ability to continue its operations and the Company has no intention nor is it forced to cease operations, or to significantly reduce the size of its operations.

Prepared by



Nguyen Thi Quynh Nga

Chief Accountant



Chu Van Long

Hai Phong, 13/03/2026

General Director



Nguyen Thi Tu Anh

020510
 CÔNG
 TNH
 KIỂM T
 THẨM Đ
 VIỆT N
 M - T

Appendix No. 02

19. Owner's equity

19.1. Increase and decrease in owner's equity

	Owner's Equity	Share capital surplus	Development and Investment Fund	Retained earnings	Total
As at 01/01/2024	203,996,300,000		174,594,214,888	41,544,595,561	420,135,110,449
Profit/(loss) in period	-	-	-	40,608,780,696	40,608,780,696
Dividend	-	-	-	(6,119,889,000)	(6,119,889,000)
Other decrease	-	-	-	(364,836,500)	(364,836,500)
As at 31/12/2024	279,473,170,000	-	124,594,214,888	50,191,780,757	454,259,165,645
As at 01/01/2025	279,473,170,000	-	124,594,214,888	50,191,780,757	454,259,165,645
Increase in capital (i)	80,486,120,000	-	(45,000,000,000)	(35,486,120,000)	-
Profit/(loss) in period	-	-	-	55,703,190,202	55,703,190,202
Dividend (ii)	-	-	-	(6,148,409,740)	(6,148,409,740)
Other decrease	-	-	-	(500,396,800)	(500,396,800)
As at 31/12/2025	359,959,290,000	-	79,594,214,888	63,760,044,419	503,313,549,307

(i) The company issues shares to increase equity from the Development Investment Fund and undistributed after-tax profit at the ratio of 100:28.8 (the owner of 100 shares will receive 28.8 additional issued shares) according to the Resolution of the General Meeting of Shareholders No. 27/NQ-DHCD-DHD dated 03/04/2025. Specifically, as follows:

- Development Investment Fund:	45,000,000,000 VND
- Undistributed after-tax profit:	35,486,120,000 VND
Total	80,486,120,000 VND

The Company has completed the change of registration for additional stock trading according to Decision No. 742/QD-SGDCKHN dated 20/06/2025 of the Vietnam Securities Depository and Clearing Corporation, whereby the number of shares registered for additional trading is 8,048,612 shares, par value 10,000 VND/share, value of additional shares registered for trading (at par value): 80,486,120,000 VND.

(ii) Payment of cash dividends from profits in 2024: VND 6,148,409,740 (rate of 2.2%) according to the Resolution of the General Meeting of Shareholders No. 27/NQ-DHCD-DHD dated 03/04/2025.

Appendix No. 01

9. Tangible fixed assets

Items	Buildings	Machinery, Equipment	Mean of Transportation	Office equipment and furniture	Total
Original cost					
As at 01/01/2025	172,733,683,489	285,473,219,986	20,264,529,754	2,945,335,539	481,416,768,768
Purchase in the period	-	221,018,342,286	-	-	221,018,342,286
Finished construction investment	-	432,066,000	-	-	432,066,000
Liquidating, disposed	-	(5,234,802,272)	(723,684,246)	(142,476,190)	(6,100,962,708)
As at 31/12/2025	172,733,683,489	501,688,826,000	19,540,845,508	2,802,859,349	696,766,214,346
Accumulated depreciation					
As at 01/01/2025	57,275,571,913	142,365,068,240	19,176,546,292	2,912,360,534	221,729,546,979
Depreciation in period	4,810,155,080	22,586,528,692	485,051,349	24,718,876	27,906,453,997
Liquidating, disposed	-	(5,234,802,272)	(723,684,246)	(142,476,190)	(6,100,962,708)
As at 31/12/2025	62,085,726,993	159,716,794,660	18,937,913,395	2,794,603,220	243,535,038,268
Net carrying amount					
As at 01/01/2025	115,458,111,576	143,108,151,746	1,087,983,462	32,975,005	259,687,221,789
As at 31/12/2025	110,647,956,496	341,972,031,340	602,932,113	8,256,129	453,231,176,078

Cost of fully depreciated tangible fixed assets but still in use:

Cost of tangible fixed assets as at 31/12/2025 formed from the science and technology development fund:

119,775,998,041
2,473,297,526

